Replication of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data

DUPLICATE - PRONOUNCE

May 14, 2021

NCT02663908

1. RCT Details

This section provides a high-level overview of a **published** RCT that the described real-world evidence study is trying to replicate as closely as possible given the remaining limitations inherent in the healthcare databases.

1.1 Title

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer (PRONOUNCE Trial)

1.2 Intended aim(s)

To compare the incidence of major cardiovascular events (MACE) among advanced prostate cancer subjects treated with degarelix versus leuprolide.

1.3 Primary endpoint for replication

Time from randomization to the first confirmed, adjudicated occurrence of a MACE, which is defined as a composite of all-cause death, nonfatal myocardial infarction, or nonfatal stroke through 12 months of ADT treatment.

1.4 Required power for primary endpoint and noninferiority margin (if applicable)

Based on prior literature, it was determined that 66 MACE events and 876 subjects would be required to reject a two-sided null hypothesis of equal hazards with 80% power at a 5% type I error rate. A hazard ratio of 0.49 with absolute event rates of 5.1% and 10.2% (degarelix vs leuprolide) were hypothesized.

1.5 Secondary endpoint for replication (assay sensitivity) and RCT finding

Secondary cardiovascular objectives: To assess 1) the frequency of MACE components individually (i.e., nonfatal myocardial infarction, nonfatal stroke, and all-cause mortality)

1.6 Trial estimate

The trial is ongoing and scheduled to complete in April 2021.

2. Person responsible for implementation of replication in Aetion

David Merola, PharmD, SM and Sushama Kattinakere Sreedhara, MBBS, MSPH, implemented the study design in the Aetion Evidence Platform. They are not responsible for the validity of the design and analytic choices. All implementation steps are recorded, and the implementation history is archived in the platform.


3. Data Source(s)

Optum CDM, IBM® MarketScan®, Medicare Diabetes

4. Study Design Diagram

The study design diagram visualizes key aspects of the longitudinal study design for expedited review.

Figure 1.



5. Cohort Identification

5.1 Cohort Summary

An active-comparator, incident-user design will be employed to compare patients that received degarelix vs. leuprolide. Subjects will be selected on the basis of having at least one diagnosis code indicating prostate cancer, male sex, and a history of atherosclerotic cardiovascular disease. Subjects will be excluded if they were not treatment-naïve with respect to prostate cancer, had a record of uncontrolled diabetes or hypertension within 30 days prior to treatment initiation, had a history of long QT syndrome or risk factors thereof (i.e., heart failure, hypokalemia, or medications known to prolong the QT interval), or an acute myocardial infarction, stroke, or revascularization procedure within 30 days prior to treatment initiation. In contrast to the PRONOUNCE trial, patients cannot be required to have had established tumor staging information, angiography-verified stenosis/occlusion of vessels, and a lack of planned cardiac surgery at the time of treatment initiation due to poor capture of this information in administrative data. All patients were required to have continuous enrollment for 365 days prior to cohort entry to ensure incident use of the study drugs.

5.2 Important steps for cohort formation

Incident use of the exposure (leuprolide or degarelix) is defined as no use of the exposure drug in the 365 days prior to meeting all eligibility criteria and initiation of exposure.

5.2.1 Eligible cohort entry dates

The degarelix indication for treatment of prostate cancer was approved by the FDA on Dec 24, 2008. Leuprolide was initially approved for the same indication prior to Dec 24, 2008.

- IBM® MarketScan®: Dec 24, 2008 December 31, 2018 (end of available data)
- Optum CDM: Dec 24, 2008 June 30, 2020 (end of available data)
- CMS Diabetes: Dec 24, 2008 Dec 31, 2017 (end of available data)
- 5.2.2 Specify <u>inclusion/exclusion</u> criteria for cohort entry and define the index date Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are provided in **Appendix** and are summarized in the flowcharts below.

5.3 Flowchart of the study cohort assembly

For Degarelix vs Leuprolide

	IBM® MarketScan®		Optum	CDM	CMS - Di	abetes
	Less Excluded Patients	Remaining Patients	Less Excluded Patients	Remaining Patients	Less Excluded Patients	Remaining Patients
All patients in our database		200,203,908		78,202,636		23,466,175
Patients with Degarelix/Leuprolide [measured between Dec 24, 2008 and Dec 31, 2019.]	-199,937,514	266,394	-78,046,787	155,849	-23,212,628	253,547
Excluded due to insufficient enrollment [-365, 0]	-94,870	171,524	-36,242	119,607	-125,589	127,958
After wash-out for prior use of reference (Leuprolide) [-365, -1]	-106,281	65,243	-77,869	41,738	-96,813	31,145
After wash-out for prior use of exposure (Degarelix) [-365, -1]	-1,959	63,284	-2,152	39,586	-3,394	27,751
Excluded because patient qualified in >1 exposure category	-2	63,282	-1	39,585	-3	27,748
Inclusion only Male gender [-365, 0]	-43,683	19,599	-17,401	22,184	-183	27,565
Inclusion Prostate Cancer [start of all available data, 0]	-784	18,815	-502	21,682	-210	27,355
Inclusion Pre-existing ASCVD [start of all available data, -30]	-14,187	4,628	-15,729	5,953	-16,099	11,256
Exclusion Androgen deprivation therapy (GnRH agonists/antagonists) [-365, 0]	-145	4,483	-106	5,847	-465	10,791
Exclusion Androgen deprivation therapy (hormonal therapy) [-365, -14]	-571	3,912	-744	5,103	-1,759	9,032
Exclusion Androgen deprivation therapy (Orchiectomy) [start of all available data, 0]	-4	3,908	-4	5,099	-9	9,023
Exclusion Uncontrolled Diabetes [-30, 0]	0	3,908	0	5,099	0	9,023
Exclusion Uncontrolled Hypertension [-30, 0]	-28	3,880	-19	5,080	-97	8,926

Exclusion Heart failure [starts of all available data, 0]	-285	3,595	-556	4,524	-1,602	7,324
Exclusion QT syndrome [starts of all available data, 0]	-7	3,588	-9	4,515	-19	7,305
Exclusion Hypokalemia [-90, 0]	-3	3,585	-14	4,501	-37	7,268
Exclusion Hypomagnesemia [-90, 0]	-9	3,576	-7	4,494	-12	7,256
Exclusion QT prolonging medicines [0, 0]	-192	3,384	-191	4,303	-446	6,810
Exclusion Acute MI [-29, 0]	-6	3,378	-9	4,294	-11	6,799
Exclusion Stroke [-29, 0]	-4	3,374	-9	4,285	-23	6,776
Exclusion Revascularization [-29, 0]	-5	3,369	-7	4,278	-6	6,770
Final cohort		3,369		4,278		6,770

6. Variables

6.1 Exposure-related variables:

Study drug:

The study exposure of interest is defined by a HCPCS/CPT code or outpatient prescription drug claim indicating degarelix administration or dispensation, respectively. New initiation will be defined by no such records of degarelix in the prior 365 days before treatment initiation (washout period) and fulfillment of study eligibility criteria.

Comparator agent:

The comparator is defined by an HCPCS/CPT code or outpatient prescription drug claim indicating leuprolide administration or dispensation, respectively. New initiation will be defined by no such records of leuprolide in the prior 365 days before treatment initiation (washout period) and fulfillment of study eligibility criteria.

6.2 <u>Preliminary Covariates:</u>

Age

The covariate listed above represents only a small subset of the covariate vector that will ultimately be controlled for in the

design and analysis. We use the covariate above only for initial feasibility analyses to judge whether there is likely to be sufficient overlap between treatment groups to proceed with the study. Remaining covariates are defined only after the study has passed the initial feasibility analysis and the initial power assessment and are listed in Table 1 (**Appendix B**). Gender is not included since the study is already restricted to male subjects.

6.3 Outcome variables and study follow-up:

6.3.1 Outcome variables

Effectiveness outcome variables of interest (definitions provided in **Appendix**):

- **Primary outcome:** MACE (all-cause death, nonfatal myocardial infarction, or nonfatal stroke through 12 months of primary treatment with leuprolide or degarelix)
- Secondary outcomes:
 - Secondary cardiovascular objectives: To assess 1) the frequency of MACE components individually (i.e., nonfatal myocardial infarction, nonfatal stroke, and all-cause mortality)

6.3.2 Study follow-up

Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on day of cohort entry. An allowable gap of 90 days between records indicating each treatment will qualify as "continuous therapy" with respect to follow-up in the as-treated analysis.

The follow-up will start the day after drug initiation (i.e., cohort entry date), and will continue until the earliest date of the following events:

- The first occurrence of the outcome of interest,
- The date of end of continuous registration in the database,
- End of the study period,
- Measured death event occurs,
- 365 days
- Switch

Discontinuation (90 days allowable grace period and risk window)

In the secondary ITT analysis, we will not censor for discontinuation or switching among study drugs

7. Initial Feasibility Analysis

Aetion report name:

For degarelix vs. leuprolide

Optum CDM- https://bwh-dope.aetion.com/projects/details/1636/rwrs/67085

IBM® MarketScan®- https://bwh-dope.aetion.com/projects/details/1323/rwrs/67083

CMS Diabetes - https://bwh-dope.aetion.com/projects/details/1637/rwrs/67081

Date conducted: 03/06/2021

Complete Aetion feasibility analysis using age as the only covariate and the primary endpoint (Section 6.3.1) as the outcome. No measures of association will be computed, nor will incidence rates be stratified by treatment group.

8. Initial Power Assessment

Aetion report name:

- For Degarelix vs Leuprolide
 - Optum CDM- https://bwh-dope.aetion.com/projects/details/1636/rwrs/67086
 - IBM® MarketScan®- https://bwh-dope.aetion.com/projects/details/1323/rwrs/67084
 - CMS Diabetes https://bwh-dope.aetion.com/projects/details/1637/rwrs/67082

Date conducted:

In order to complete the initial power analysis, a dummy outcome indicating a 90-day gap in database enrollment will be used. This outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. A 1:1 PS-matched comparative analysis was performed, including age as the only covariate. Power calculations are based on the formulas from Chow et al. (2008).

• Stop analyses until feasibility and power are reviewed by primary investigators and FDA. Reviewers evaluate the results of the analyses described above in Sections 7 and 8, including numbers of patients, patient characteristics, follow-up time, and reasons for censoring by treatment group, as well as overall rates of outcomes and study power. These parameters are re-evaluated and reported in the subsequent sections, after incorporating feedback and refining the protocol.

Stop analyses until feasibility and power are reviewed by primary investigators, FDA, and assigned members of advisory board.

Reviewed by PI:	Shirley Wang	Date reviewed:	3/17/2021
Reviewed by FDA:	Ken	Date reviewed:	4/3/2021
Reasons for stopping			
analysis (if required):			

9. Balance Assessment

Aetion report name:

For Degarelix vs. leuprolide

Optum CDM- https://bwh-dope.aetion.com/projects/details/1636/rwrs/68435
IBM® MarketScan®- https://bwh-dope.aetion.com/projects/details/1637/rwrs/68434
CMS Diabetes - https://bwh-dope.aetion.com/projects/details/1637/rwrs/68434

<u>Date conducted:</u> 04/14/2021

After review of initial feasibility and power analyses, complete creation of the remaining covariates from Section 6.2. Again, using the dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS should include the complete list of covariates.

• Provide plot of PS distributions stratified by treatment group.

Note- Please refer to Appendix_Table1_PRONOUNCE_v1 (worksheet named 'PS matching').

· Report covariate balance after matching.

Note- Please refer to Appendix Table 1 PRONOUNCE v1 (worksheet named 'Table 1').

• Report reasons for censoring by treatment group.

	Overall	Referent	Exposure
Start of an additional exposure	1147 (30.39%)	1 (0.05%)	1146 (60.73%)
End of index exposure	2084 (55.22%)	1645 (87.18%)	439 (23.26%)
Specified date reached	157 (4.16%)	78 (4.13%)	79 (4.19%)
Maximum follow-up reached (365 days)	142 (3.76)	42 (2.23%)	100 (5.30%)
End of patient enrollment	244 (6.46%)	121 (6.41%)	123 (6.52%)

• Report follow-up time by treatment group.

Median Follow-Up Time (Days) [IQR]							
Patient Group Optum CDM IBM® MarketScan® CMS - Diabetes							
Overall Patient Population	89 [64, 116]	89 [55, 118]	89 [61, 109]				
Referent	89 [89, 89]	89 [89, 89]	89 [89, 89]				
Exposure	82 [33, 140]	67 [31, 126]	68 [33, 125]				

• Report overall risk of the primary outcome.

	Optum CDM	IBM® MarketScan®	CMS - Diabetes	Pooled
Risk per 1,000 patients	25.28	12.77	31.17	25.12

10. Final Power Assessment

Date conducted: 4/15/2021

Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9. All other parameters in the table should be the same as in Section 8.

Pooled

Superiority Analysis	
Number of patients matched	3,774
Reference	1,887
Exposed	1,887
Risk per 1,000 patients	25.12
Desired HR from RCT	0.49
Alpha (2-sided)	0.05
Number of events expected	94.80288
Power	0.93484302

• Optum CDM

Superiority Analysis	
Number of patients matched	1,092
Reference	546
Exposed	546
Risk per 1,000 patients	25.28
Desired HR from RCT	0.49
Alpha (2-sided)	0.05
Number of events expected	27.60576
Power	0.465815489

• IBM® MarketScan®

Superiority Analysis	
Number of patients matched	830
Reference	415
Exposed	415
Risk per 1,000 patients	12.77
Desired HR from RCT	0.49
Alpha (2-sided)	0.05
Number of events expected	10.5991
Power	0.21311438

• CMS - Diabetes

Superiority Analysis	
Number of patients matched	1,852
Reference	926
Exposed	926
Risk per 1,000 patients	31.17
Desired HR from RCT	0.49
Alpha (2-sided)	0.05
Number of events expected	57.72684
Power	0.773370349

• Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of advisory board.

Reviewed by PI:	Shirley Wang	Date reviewed:	4/16/2021
Reviewed by FDA:		Date reviewed:	
Reasons for stopping			
analysis (if required):			

11. Study Confidence and Concerns

<u>Deadline for voting on study confidence and listing concerns:</u>
<u>Date votes and concerns are summarized:</u>

- If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps.
- All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the success of the RWD study in the Google Form. This form also provides space for reviewers to list any concerns that they feel may

contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the individual respondent.

• After the deadline for voting has passed, provide the distribution of responses and summarize all concerns here.

12. Register study protocol on clinicalTrials.gov

Date conducted:

• Register the study on <u>clinicalTrials.gov</u> and upload this document.

13. Comparative Analyses

Aetion report name:

Date conducted:

- 13.1 For primary analysis:
- 13.2 For sensitivity analyses:

14. Requested Results

14.1 <u>Table 1: Baseline characteristics before and after adjustment</u>

Variable	Before adjustment			After adjust	After adjustment		
	Referent	Exposure	Std. diff.	Referent	Exposure	Std. diff.	
Number of patients			-			-	
Age categories							

14.2 <u>Table 2: Follow-up time</u>

Patient Group	Median Follow-Up Time (Days) [IQR]
Overall Patient Population	
Referent	
Exposure	

14.3 <u>Table 3: Censoring events</u>

	Overall	Referent	Exposure
Outcome			
Death			
Start of an additional exposure			
End of index exposure			
Specified date reached			
End of patient data			
End of patient enrollment			

14.4 <u>Table 4: Results from primary analyses;</u>

Analysis	No. exposed events	No. referent events	Exposed rate	Referent rate	HR (95% CI)
Crude					
Analysis 1					
Analysis 2					

HR, Hazard Ratio; CI, Confidence Interval.

14.5 <u>Table 5: Results from secondary analyses;</u>

15. References

Chow S, Shao J, Wang H. 2008. *Sample Size Calculations in Clinical Research*. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. page 177

Appendix A

Information from Trial

<u>Trial Name:</u> PRONOUNCE https://www.clinicaltrials.gov/ct2/show/NCT02663908

NCT: NCT02663908

Therapeutic Area: Oncology

RCT Category: Equivalence/Superiority

Brand Name: Firmagon

Generic Name: Degarelix

Sponsor: Ferring Pharmaceuticals

Year: 2016 - Present

Measurable Endpoint: MACE

Exposure: Degarelix

Comparator: Leuprolide

Populuation: Men of any age with with advance prostate cancer and predefined CV disease

No. of Patients: TBD

Power: TBD

Appendix A

	PRONOUNCE trial definitions	Implementation in routine care		Out on a disco
	PRONOUNCE trial definitions	***************************************	References/Rationale Please see the following Google Drive for further details or any missing information:	Color coding
		TRIAL DETAILS	Please see the following Google Drive for further details or any missing information: https://drive.google.com/open?id=1WD618wnyW?jEAXst.TcuK-VCcnb68-gV	Criteria
			ICD-10 codes are not listed in this document because of excel cell size limitations and excessive number of ICD-10 codes. Full ICD-10 code lists will be available in the above Google Drive Folder (link above) ICD-8 to ICD-10 code conversions.	
			full ICP-10 code lists will be available in the above Google Prive Folder films above NCO-3 to NCO-10 code conversions, serie completed using a SSS macro that implements forward? backward mapping based on the CNS ICD-9 to ICD-10 mapping: http://www.nbs-org/data/cd9-4cd-30-cm-and-oper-crosswalk-general-equivalence-mapping.html	
		EXPOSURE vs. COMPARISON	тарину, теркуу жимлик олуучка получен достина услегозичко услега недоставлентарунау пол	Can be replicated in claims
VS.	x 1 month, Degarelix 80mg SC q mt x 11 months thereafter	<u>Degarelix Arm</u> : Generic name: Degarelix Acetate; HCPCS/CPT: J915S (inpatient and outpatient) vs.		Using dummy definitions for measuring in claims
Leuprolide IM 22.5mg q 3 m	months x 12 months	Leuprolide Arm: Generic name: Leuprolide Acetate; HCPCS/CPT: J1950, C9430, J9219, J9218, J9217 (inpatient and outpatient)		Can't he measured in claims
		Measured from first day following expoure initiation		
		Death: Inpatient death indicated by discharge date		
		Seafort Mic 70 - Slagonic - 416 to GETF - 410.2 20 - 50 - 50 - 50 - 50 - 50 - 50 - 50 -		
MACE (All-cause death, nonfata	atal myocardial infarction, nonfatal stroke)	Norfatal Stroke: Stroke (ischemic/hemorrhagic): ICD-9 diagnosis: "430", "431", "433.01", "433.11", "433.31", "433.31", "433.91", "434.01", "434.01", "434.01", "434.01", "434.11", "434.91", "436.00", "431", "435.00", "431", "433.01", "43	Source: CANVAS trial (https://bwh-dope.aetion.com/measures/details/92945/661/0/basics)	Can't be measured in claims but not important for the analysis
		\$5.09 \$63.00 \$63.01 \$63.02 \$63.09 \$63.00 \$63.01 \$63.11 \$63.12 \$63.19 \$63.19 \$63.10 \$63.11 \$63.12 \$63.19 \$63.10 \$63.11 \$63.12 \$63.19 \$63.19 \$63.10 \$63.11 \$63.12 \$63.19 \$63.10 \$63.11 \$63.12 \$63.19 \$63.10 \$63		
		63.511 (63.512 (63.519 (63.521 (63.523 (63.531 (63.531 (63.542		
		INCLUSION CRITERIA		
		Measured from (start of all available data, 0). Must have both, diagnosis code and male gender for inclusion.	Male patients with 1 dx code + an exposure provides enough information to confirm diagnosis, as the exposures have very few or no indications outside of advanced PC	
1 Histologically confirmed ad	idenocarcinoma of the prostate	Malignant Neoplasm of the Prostate: ICD 9 diagnosis: 185:xxx	Necessitating code for biopsy may exclude subjects with prevalent prostate cancer if they were initially	
		ICD-10 diagnosis; C61.x (inpatient and outpatient)	diagnosed prior to database enrollment with early stage disease	
		See: Male	Lupron is indicated in females for endometriosis. Restricting to males helps ensure indication of interest.	
Tumor, node, metastasis sta study start	staging available before treatment start (bone scan and/or CT scan and/or MRI) <12 weeks before			
	s initiate continued ADT therapy with intended duration of 12 months or leaner			
-Patients with metastati	initiate continued ADT therapy with intended duration of 12 months or longer till protate cancer at time of diagnosis cancer who develop metasses after local therapy cancer with very high-risk, high-risk, or intermediate risk disease with feature of unfavorable etcel with definition addisort therapy in combination with at least 12 months of			
Patients with prostate c	e cancer with very high-risk, high-risk, or intermediate risk disease with feature of unfavorable			
prognosis who will be treate neoadjuvant/adjuvant ADT	ated with definitive radiation therapy in combination with at least 12 months of T			
		Measured from [start of all available data , -30] in an inpatient or outpatient care setting in any diagnosis position		
Pre-existing ASCAID (efi-	rmed diagnosis, documented) according to at least 1 of the following criteria.	Acute or old MI:		
-Previous myocardial inf:	rmed diagnosis, documented) according to at least 1 of the following criteria nfarction >=30 days before randomization	SCD-9 disagnosis: 410.xx , 412.xx SCD-10 disagnosis: 121.01, 121.02, 121.09, 121.11, 121.19, 121.21, 121.29, 121.3, 121.4, 122.0, 122.1, 122.2, 122.8, 122.9, 125.2		
Previous revascularization Coronary artery: stent pl	ition procedure >=30 days before randomization placement/balloon angioplasty or coronary artery bypass graft surgery	Company of the Company Company of the Company of th	Sources: DUPLICATE Standard Measures ("MI (Inc3 HF Algorithm)", "Old MI with ICD 10 Copy")	
 Carotid artery: stent plan Iliac, femoral, popliteal 	placement/balloon angioplasty or coronary artery bypass graft surgery (acement/balloon angioplasty or endarterectomy surgery al arteries: stent placement/balloon angioplasty or vascular bypass surgery	(CD-9 procedure: "00.66", "36.03", "36.06", "36.07", "36.09", "36.13", "36.32", "36.33", "36.34", "36.10", "36.11", "36.12", "36.13", "36.14", "36.15", "36.16", "36.16", "36.16", "36.16", "36.16", "36.17", "36.18", "36.		
		ICD-10 procedure: see Appendix HEPCS/(PT: "35302", "35356", "35363", "35372", "35372", "35381", "35483", "35483", "35521", "35533", "35539", "35540", "35540", "35540", "35540", "35549", "35551", "35555", "35556", "35556", "35565", "35665	DUPLICATE Standard Measures ("Old MI with ICD 10 Copy", "Information on Outcome- Coronary revascularization (PTCA, stenting, CABG) v5 -WITH ICD-10 CODES")	
		"35646", "35647", "35651", "35654", "35656", "35666", "35665", "35666", "34201", "34203", "34421", "34451", "35303", "35571", "35623", "35671"	revascularization (PTCA, stenting, CABG) v5 -WITH ICD-10 CODES")	
-Coronany arteny	is >=50% at any time point before randomization by angiography or CT angiography			
-Carotid artery -Iliac, femoral, or poplite	iteal arteries			
-Carotid ultrasound result	Iteal arteries rults that documented a vascular stenoois >>50% at any time point before randomization re index <0.9 at any time point before randomization			
		EXCLUSION CRITERIA		
		Measured [-365, 0] in an inpatient or oupatient care setting in any diagnosis position		
Patients must be treatment	nt-naive (ADT)	GriPH Agonists: generic name: goverelin, triptorelin, histrelin HEPCS/CPT: goverelin: 19202 59560; triptorelin: 13315 13315 histrelin: 11675 19225 19226 Q2020 S0133 (inpatient and outpattent)	Source:https://jamanetwork.com/journals/jamaoncology/article-abstract/2476248	
1 months before randomizati	ition	Measured (-365, -14)	Patients may fill prescription and initiate androgen blockade ~1-2 weeks prior to start of LHRH agonist for flare	
 Any additional hormonal initial flare protection is alle 	increaser (unif) evicus ADT for necadjuvant or adjuvant therapy, then the last dose of therapy must be at least 12 tition all therapy upfront (i.e., abiraterone) is prohibited in the study; however, anti-androgen use for illowed for a maximum period of up to 28 days after randomization		protection	
		Harmonal Therapy: generic name: abiraterone, ketoconazole, flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, finasteride, dutasteride HEPCS/COT: flutamide: 50175 finasteride: 50138		
		Measured from (start of all available data , 0) in an inpatient and outpatient care setting in any diagnosis position:		
		Orchiectomy: HCPCS/CPT: 54520, 54522, 54530, 54535, 54690 (54521 not found in databases)		
		CD-9 procedure: 62.3x, 62.4x (Inpatient and outpatient) CD-10 procedure: "0VT90ZZ", "0VT94ZZ", "0VT84ZZ", "0VTC0ZZ", "0VTC0ZZ"	Source:https://jamanetwork.com/journals/jamaoncology/article-abstract/2476248	
Previous or current hormona	inal management of prostate cancer	Measured [-365, 0]:	patients may initiate androgen blockade for flare within 14 days of initial treatment, which is permissible per	
-Surgical castration -Any hormonal manipular	alation	GRRH Agoelsts: generic name: goserelin, triptorelin, histrelin	PRONOUNCE selection criteria	
	vant/adjuvant hormonal therapy, unless treatment terminated >12 months before study start	ICPCS/CPT: gonerellin: 19202 59560; triptorellin: 13315 13316 histrellin: 11675 19225 19226 Q2020 50133 (inpatient and outpatient)	Abarelix was not included, as it was only on the market for a short-period of time prior to the span of our data resources. Cetrorelix and ganirelix are also excluded from this analysis since they're not indicated for prostate	
		Measured (-365, -14):	cancer.	
		Hormonal Therapy: generic name: abiraterone, ketoconazole, flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, finasteride, dutasteride		
		HEPCS/CPT: flutamide: S0175 finasteride: S0138		
		Measured [-30, 0] in an inpatient care setting in a primary diagnosis position		
		Uncontrolled Diabetes	Common Contra from Profilents absorbed account filters (butter (files)	
3 Uncontrolled type 1 or type				1
,, , , , , , , , , , , , , , , , , , , ,	se 2 diabetes mellitus (defined as HbA1c >10%) at time of randomization	<u>NO-10:</u> R73.09, R73.9	Source: Codes from Duplicate standard measure library (https://bwh- dope.aetion.com/measures/details/306630/0/0/templates/simpleEventSet?tab=3)	
	e 2 diabetes mellitus (defined as HbA1c >10%) at time of randomization	300 (2010), R73.9	An inpatient, primary diagnosis of hyperglycemia is thought to be a good proxy for uncontrolled diabetes based	
	e 2 diabetes mellitus (defined as HbA1c >10%) at time of randomization	300 (700), 7739		
	diabetes mellitus (defined as HbA1c >10%) at time of randomization	<u>550 10</u> 872.09, 872.9	An inpatient, primary diagnosis of hyperglycemia is thought to be a good proxy for uncontrolled diabetes based	
	e 2 diabetes mellitus (defined as HBAI.c >10%) at time of randomization	202.10, F72.00, R72.9 Measured 30, 0] (CD-10 measured in other an inpatient or outpatient care setting in any diagnosis position. ICD-9 measured in an inpatient care setting or ED setting in a primary diagnosis position:	An inpatient, primary diagnosis of hyperglycemia is thought to be a good proxy for uncontrolled diabetes based	
		202.10, F72.00, R72.9 Measured 30, 0] (CD-10 measured in other an inpatient or outpatient care setting in any diagnosis position. ICD-9 measured in an inpatient care setting or ED setting in a primary diagnosis position:	An inpatient, primary diagnosis of hyperglycemia is thought to be a good proxy for uncontrolled diabetes based	
4 Uncontrolled hypertension (us 2 diabetes mellitus (defined as HAXL: >10%) at time of randomization 1 (SEP >180 mm Hg or DEP >110 mm Hg) at time of randomization	<u>550 10</u> 872.09, 872.9	An inpatient, primary diagnosis of hyperglycemia is thought to be a good proxy for uncontrolled diabetes based	
4 Uncontrolled hypertension (202.10, F72.00, R72.9 Measured 30, 0] (CD-10 measured in other an inpatient or outpatient care setting in any diagnosis position. ICD-9 measured in an inpatient care setting or ED setting in a primary diagnosis position:	An inpatient, primary diagnosis of hyperglycenia is thought to be a good proxy for uncontrolled diabetes based on the investigation's destantive knowledge.	
4 Uncontrolled hypertension (202.10, F72.00, R72.9 Measured 30, 0] (CD-10 measured in other an inpatient or outpatient care setting in any diagnosis position. ICD-9 measured in an inpatient care setting or ED setting in a primary diagnosis position:	An inpatient, primary diagnosis of hyperglycenia is thought to be a good proxy for uncentrolled diabetes based on the investigation's distributive broad-ledge. Source: CUPLICATE Team (EMPEROR-Preserved trial)	
4 Uncontrolled hypertension (ISO 10: 173.09, 873.9 Measured [35, 6] CD-1D measured in other an inpatient or outpatient care setting in any diagnosis position. CD-5 measured in an inpatient care setting or CD setting in a primary diagnosis position. Solid grave hypertension/Hypertension/CD-10. Solid graves and the setting or CD setting in a primary diagnosis position. Solid graves and the setting or CD setting in a primary diagnosis position. Solid graves and the setting or CD setting in a primary diagnosis position. Measured [Isan of all available data, 0] in an inpatient or outpatient care setting in any diagnosis position.	An inpatient, primary diagnosis of hyperglycenia is thought to be a good proxy for uncentrolled diabetes based on the investigation's distributive broad-ledge. Source: CUPLICATE Team (EMPEROR-Preserved trial)	
4 Uncontrolled hypertension (20.10. F73.05, 6729 Measure[30, 0] KD-1D measured in other an inpatient or outpatient care setting in any diagnosis position. KD-9 measured in an inpatient care setting or ED setting in a primary diagnosis position: Measure[150, 0] KD-1D measured in other an inpatient or outpatient care setting in any diagnosis position. Measure[150, 0] KD-1D measured in an inpatient or outpatient care setting in any diagnosis position. Measured [150, 0] KD-1D measured in other an inpatient or outpatient care setting in any diagnosis position. Measured [150, 0] KD-1D measured in an inpatient or outpatient care setting in any diagnosis position. Measured [150, 0] KD-1D measured in an inpatient or outpatient care setting in any diagnosis position.	An inpatient, primary diagnosis of hyperglycenia is thought to be a good proxy for uncentrolled diabetes based on the investigation's distributive broad-ledge. Source: CUPLICATE Team (EMPEROR-Preserved trial)	
4 Uncontrolled hypertension (Each 10, 173.00, 172.9 Measured [34, 6] CD-10 measured in either an inpatient or outpatient care setting in any diagnosis position. ICD-9 measured in an inpatient care setting or ID setting in a primary diagnosis position. Measured [34, 6] CD-10 measured in either an inpatient or outpatient care setting in any diagnosis position. Measured [34, 6] CD-10 measured in either an inpatient care setting in a primary diagnosis position. Measured [34, 6] CD-10 measured in either an inpatient care setting in any diagnosis position. Log of Sendones. CD-10 diagnosis [35, 6] CD-10 measured in either an inpatient or outpatient care setting in any diagnosis position. Log of Sendones. CD-10 diagnosis [34, 6] CD-10 measured in either an inpatient or outpatient care setting in any diagnosis position.	An inpatient, primary diagnosis of hyperglycenia is thought to be a good proxy for uncentrolled diabetes based on the investigation's distributive broad-ledge. Source: CUPLICATE Team (EMPEROR-Preserved trial)	
4 Uncontrolled hypertension (CO.10. 177.00, 872.9 Measured (34, 0) (CO-10 measured in either an inpatient or outpatient care setting in any diagnosis position. XCD-9 measured in an inpatient care setting or ID setting in a primary diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient or outpatient or outpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in a primary diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in a primary diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in a primary diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in any diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in an inpatient care setting in a primary diagnosis position. Measured (34, 0) (CO-10 measured in either an inpatient care setting in a primary diagnosis	An inpatient, primary diagnosis of hyperglycenia is thought to be a good proxy for uncentrolled diabetes based on the investigation's distributive broad-ledge. Source: CUPLICATE Team (EMPEROR-Preserved trial)	
Uncontrolled hypertension {		ESCALO, R72.0, R72.9 Measured [30, 0] CD-10 measured in either an inpatient or outpatient cure setting in any diagnosis position. XCD-9 measured in an inpatient cure setting or ID setting in a primary diagnosis position. Molignant hypotransion/Hypotr	An inpatient, primary diagnosis of hyperglycenia is thought to be a good proxy for uncentrolled diabetes based on the investigation's distributive broad-ledge. Source: CUPLICATE Team (EMPEROR-Preserved trial)	
	i (SEP > 180 mm Hg or DEP > 110 mm Hg) at time of randomization	66-saured [36, 6] CD-10 measured in either an inpatient or outpatient care setting in any diagnosis position. KD-9 measured in an inpatient care setting or ID setting in a primary diagnosis position. Malignatis hourstandor/Napartamber colds: 60-5 desences, 1943, 1943, 1941, 4012, 4010, 4010, 4040, 405.0, 4019, 417.2, 796.2 CD-10 desences; 1943, 1943	An inpatient, primary diagnosis of hyperglycenia is thought to be a good proxy for uncontrolled diabetes based on the investigation's sketsetive knowledge. Source: CUPFLCATE Team (EMPEROR Preserved trial) Mullignant HTN clinically defined as SBP-180mmHg Source: CUPFLCATE Standard Measure ("Heart Failure (CHF) Ever Lookback"); CPRD Measure Library	
A history of connectiful local	t (SBP > 150 mm kg or DBP > 110 mm kg) at time of randomization	Measured [34, 0] (CD-10 measured in either an inpatient or outpatient care setting in any diagnosis position. XCD-9 measured in an inpatient care setting or ID setting in a primary diagnosis position. Measured [34, 0] (CD-10 measured in either an inpatient or outpatient care setting in any diagnosis position. Measured [34, 0] (CD-10 measured in either an inpatient or outpatient or outpatient care setting in any diagnosis position. Measured [34, 0] (CD-10 measured in either an inpatient or outpatient care setting in any diagnosis position. Measured [34, 0] (CD-10 measured in either an inpatient care setting in any diagnosis position. Measured [34, 0] in an inpatient code or 2 outpatient code in any diagnosis position. Measured [34, 0] in an inpatient code or 2 outpatient code in any diagnosis position. CD-10 diagnosis (24, 28, 38, 34, 020, 4, 031, 4, 031, 4, 041, 4, 041, 4, 041, 51; CD-10 diagnosis (24, 28, 38, 34, 020, 4, 031, 4, 031, 4, 041, 4, 041, 4, 041, 51; CD-10 diagnosis (24, 28, 38, 34, 020, 4, 031, 4, 031, 041, 041, 041, 041, 041, 041, 041, 04	An ingustions, primary diagnosis of hyperglycenia is thought to be a good proxy for uncontrolled diabetes based on the investigators' substantive knowledge. Source: CUPILATE Team (EMPEROR-Preserved brist) Malignant HTM closeably defined as \$897-180mming Source: CUPILATE Standard Measure ("Heart Failure (OP) Ever Lookback"); CMD Measure Library ("MERAT, Tecket, 13), CMP rotinging drugs"). Aetion Search, Aetion Search	
A history of connailth long	i (SEP > 180 mm Hg or DEP > 110 mm Hg) at time of randomization	Measured [30, 0] (CD-10 measured in other an inpatient or outpatient care setting in any diagnosis position. ICD-9 measured in an inpatient care setting or ID setting in a primary diagnosis position. Maligneth Physitemetric Physitemetric Physitemetric Care Setting in any diagnosis position. ICD-9 measured in an inpatient care setting or ID setting in a primary diagnosis position. Maligneth Physitemetric Physitemetric Care Setting in any diagnosis position. Maligneth Sp. 361.1, 401.0, 401.0, 401.0, 401.0, 401.0, 401.9, 417.2, 796.2 CD-10 diagnosis: 10.0 and inpatient or outpatient care setting in any diagnosis position. Maligneth Sp. 361.1, 401.0,	An ingustions, primary diagnosis of hyperglycenia is thought to be a good proxy for uncontrolled diabetes based on the investigators' substantive knowledge. Source: CUPILATE Team (EMPEROR-Preserved brist) Malignant HTM closeably defined as \$897-180mming Source: CUPILATE Standard Measure ("Heart Failure (OP) Ever Lookback"); CMD Measure Library ("MERAT, Tecket, 13), CMP rotinging drugs"). Aetion Search, Aetion Search	
A history of connailth long	t (SBP > 150 mm kg or DBP > 110 mm kg) at time of randomization	Measured (34, 6) (CD-10 measured in either an injustient or outpatient care setting in any diagnosis position KD-9 measured in an injustient care setting or ID setting in a primary diagnosis position KD-9 measured in an injustient care setting or ID setting in a primary diagnosis position KD-9 measured in an injustient care setting or ID setting in a primary diagnosis position KD-9 measured in an injustient care setting in any diagnosis position in an injustient or outpatient or outpatient care setting in any diagnosis position in any diagnosis position in any diagnosis position in any diagnosis diagnosis (48.5). The AD-10 setting in an injustient code or 2 outpatient codes in any diagnosis position in any diagnosis (48.5). The AD-10 setting in any diagnosis position in any diagnosis (48.5). The AD-10 setting in any diagnosis position in any diagnosis (48.5). The AD-10 setting in any diagnosis position in any diagnosis (48.5). The AD-10 setting in an inpatient code of the AD-10 setting in any diagnosis (48.5). The AD-10 setting in an inpatient code of the AD-10 setting in any diagnosis (48.5). The AD-10 setting in any diagnosis (48.5). The AD-10 setting in any diagnosis (48.5). The AD-10 setting in an inpatient code of the AD-10 setting in any diagnosis (48.5). The AD-10 setting in any diagnosis (48.5). The AD-10 setting in	An inpatient, primary diagnosis of hyperglycenia is thought to be a good proxy for uncontrolled diabetes based on the investigation's sketsetive knowledge. Source: CUPFLCATE Team (EMPEROR Preserved trial) Mullignant HTN clinically defined as SBP-180mmHg Source: CUPFLCATE Standard Measure ("Heart Failure (CHF) Ever Lookback"); CPRD Measure Library	
A history of connailth long	t (SBP > 150 mm kg or DBP > 110 mm kg) at time of randomization	Measured [30, 8] CD-10 measured in other an inputient or outpatient care setting in any diagnosis position. XCD-9 measured in an inputient care setting or ID setting in a primary diagnosis position. Measured [30, 8] CD-10 measured in internal inputient or outpatient care setting in any diagnosis position. XCD-9 measured in an inputient care setting or ID setting in a primary diagnosis position. Measured [30, 8] CD-10 measured in an inputient or outpatient care setting in any diagnosis position. Measured [151, 10] As a substitute of all available data, [9] in an inputient care setting in any diagnosis position. Measured [30, 6] (CD-10 measured in any diagnosis position care setting in any diagnosis position. Measured [30, 6] (CD-10 measured in any diagnosis position care setting in any diagnosis position. Measured [30, 6] (CD-10 measured in any diagnosis position. Meas	An ingustions, primary diagnosis of hyperglycenia is thought to be a good proxy for uncontrolled diabetes based on the investigators' substantive knowledge. Source: CUPILATE Team (EMPEROR-Preserved brist) Malignant HTM closeably defined as \$897-180mming Source: CUPILATE Standard Measure ("Heart Failure (OP) Ever Lookback"); CMD Measure Library ("MERAT, Tecket, 13), CMP rotinging drugs"). Aetion Search, Aetion Search	
Abistos of consolità lon	t (SBP > 150 mm kg or DBP > 110 mm kg) at time of randomization	Measured [30, 0] ICD-1D measured in other an inpatient or outpatient care setting in any diagnosis position. ICD-9 measured in an inpatient care setting or ID setting in a primary diagnosis position. Moligonath inpatient (AD-9 measured in an inpatient care setting in a primary diagnosis position. ICD-9 measured in an inpatient care setting in a primary diagnosis position. Moligonath inpatient of all availables data, 0] in an inpatient or outpatient care setting in any diagnosis position. Moligonath inpatient of all availables data, 0] in an inpatient or outpatient care setting in any diagnosis position. Moligonath inpatient of all availables data, 0] in an inpatient or outpatient care setting in any diagnosis position. Moligonath inpatient of all availables data, 0] in an inpatient code or 2 outpatient codes in any diagnosis position. Moligonath inpatient code or 2 outpatient codes in any diagnosis position. Moligonath inpatient code or 2 outpatient codes in any diagnosis position. Moligonath inpatient code or 2 outpatient codes in any diagnosis position. Moligonath inpatient code or 2 outpatient codes in any diagnosis position. Moligonath inpatient codes or 2 outpatient codes in any diagnosis position. Moligonath inpatient codes or 2 outpatient codes in any diagnosis position. Moligonath in an inpatient code or 2 outpatient codes in any diagnosis position. Moligonath in an inpatient code or 2 outpatient codes in any diagnosis position. Moligonath in an inpatient code or 2 outpatient codes in any diagnosis position. Moligonath in an inpatient code or 2 outpatient codes in any diagnosis position. Moligonath in an inpatient code or 2 outpatient codes in any diagnosis position. Moligonath in an inpatient code or 2 outpatient codes in any diagnosis position. Moligonath in an inpatient code of 2 outpatient codes in any diagnosis position. Moligonath in an inpatient code of 2 outpatient codes in any diagnosis position. Moligonath in an inpatient code outpatient codes in any diagnosis position. Mo	An ingustions, primary diagnosis of hyperglycenia is thought to be a good proxy for uncontrolled diabetes based on the investigators' substantive knowledge. Source: CUPILATE Team (EMPEROR-Preserved brist) Malignant HTM closeably defined as \$897-180mming Source: CUPILATE Standard Measure ("Heart Failure (OP) Ever Lookback"); CMD Measure Library ("MERAT, Tecket, 13), CMP rotinging drugs"). Aetion Search, Aetion Search	
Abistos of consolità lon	t (SBP > 150 mm kg or DBP > 110 mm kg) at time of randomization	Measured [54, 6] (CD-10 measured in either an inpatient or outpatient care setting in any diagnosis positionKD-9 measured in an inpatient care setting or ED setting in a primary diagnosis position. Molignant Proportion Mayorization (Hypertacobia) cubic 50 6 aleganesis (45) a. 80.21.1. 401.0. 402.0., 403.	An ingustions, primary diagnosis of hyperglycenia is thought to be a good proxy for uncontrolled diabetes based on the investigators' substantive knowledge. Source: CUPILATE Team (EMPEROR-Preserved brist) Malignant HTM closeably defined as \$897-180mming Source: CUPILATE Standard Measure ("Heart Failure (OP) Ever Lookback"); CMD Measure Library ("MERAT, Tecket, 13), CMP rotinging drugs"). Aetion Search, Aetion Search	
A history of committed long	t (SBP > 150 mm kg or DBP > 110 mm kg) at time of randomization	Measure [30, 8] CD-10 measured in other an inputient or outpatient care setting in any diagnosis position. XD-9 measured in an inputient care setting or ID setting in a primary diagnosis position. Measure [30, 8] CD-10 measured in an inputient or outpatient care setting in any diagnosis position. XD-9 measured in an inputient care setting or ID setting in a primary diagnosis position. Measured [15, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10	An ingustions, primary diagnosis of hyperglycenia is thought to be a good proxy for uncontrolled diabetes based on the investigators' substantive knowledge. Source: CUPILATE Team (EMPEROR-Preserved brist) Malignant HTM closeably defined as \$897-180mming Source: CUPILATE Standard Measure ("Heart Failure (OP) Ever Lookback"); CMD Measure Library ("MERAT, Tecket, 13), CMP rotinging drugs"). Aetion Search, Aetion Search	

Appendix A

6	Within 30 days before randomination: Application infection -trainel (hemorrally circlemic) -coronary, carotid, or peripheral artery revascularization	DUPLICATE Standard Measure ("Information on Outcome - Stroke WITH ICD-10 CODES [Inpatient, PRIMARY)", "Acute Mil [INVER LODING ACQ ")	
7	Planned or scheduled cardiac surgery or PCI procedure that is known at the time of randomization		<u> </u>




Table 1: Unmatched

			UNMA	TCHED								
		Optum	Oldivir	Marketscan				Medicare			Poole	d
Variable	Leuprolide		St. Diff	Leuprolide	Degarelix	St. Diff	Leuprolide	Degarelix	St. Diff	Leuprolide	Degarelix	St. Diff
Number of patients	3,681	597		2,938	431		5,829	941		12,448	1,969	
Year of Cohort Entry Date												
2008-2009; n (%)	262 (7.1%)	0 (0.0%)	0.39	312 (10.6%)	0 (0.0%)	0.49	353 (6.1%)	0 (0.0%)	0.36	927 (7.4%)	0 (0.0%)	0.40
2010; n (%)	265 (7.2%)	21 (3.5%)	0.16	358 (12.2%)	24 (5.6%)	0.23	427 (7.3%)	37 (3.9%)	0.15	1,050 (8.4%)	82 (4.2%)	0.17
2011; n (%)	263 (7.1%)	25 (4.2%)	0.13	421 (14.3%)	45 (10.4%)	0.12	467 (8.0%)	49 (5.2%)	0.11	1,151 (9.2%)	119 (6.0%)	0.12
2012; n (%)	245 (6.7%)	41 (6.9%)	-0.01	377 (12.8%)	50 (11.6%)	0.04	485 (8.3%)	69 (7.3%)	0.04	1,107 (8.9%)	160 (8.1%)	0.03
2013; n (%)	241 (6.5%)	54 (9.0%)	-0.09	357 (12.2%)	56 (13.0%)	-0.02	757 (13.0%)	121 (12.9%)	0.00	1,355 (10.9%	231 (11.7%)	-0.03
2014; n (%)	247 (6.7%)	38 (6.4%)	0.01	268 (9.1%)	48 (11.1%)	-0.07	888 (15.2%)	177 (18.8%)	-0.10	1,403 (11.3%	263 (13.4%)	-0.06
2015; n (%)	258 (7.0%)	44 (7.4%)	-0.02	257 (8.7%)	66 (15.3%)	-0.20	1,009 (17.3%	171 (18.2%)	-0.02	1,524 (12.2%	281 (14.3%)	-0.06
2016; n (%)	322 (8.7%)	67 (11.2%)	-0.08	281 (9.6%)	65 (15.1%)		784 (13.4%)			1,387 (11.1%		-0.09
2017; n (%)	399 (10.8%)	78 (13.1%)		193 (6.6%)	50 (11.6%)		659 (11.3%)	169 (18.0%)	-0.19	1,251 (10.0%	297 (15.1%)	-0.15
2018; n (%)	435 (11.8%)	86 (14.4%)	-0.08		27 (6.3%)	-0.11						
2019; n (%)	479 (13.0%)	103 (17.3%)	-0.12									
2020; n (%)	265 (7.2%)	40 (6.7%)	0.02									
Age												
mean (sd)		75.93 (7.65)		74.38 (9.05)			76.85 (6.58)			75.93 (7.48)		-0.02
median [IQR]	76.00 [71.00,	76.00 [71.00,	0.00	75.00 [68.00	75.00 [68.00,	0.00	76.00 [72.00,	77.00 [72.00]	, -0.15	75.76 (8.66)	76.26 (8.81)	-0.06
Region												
1 - Northeast; n (%)	366 (9.9%)	99 (16.6%)		423 (14.4%)			1,018 (17.5%			1,807 (14.5%		-0.14
2 - North Central; n (%)	1,037 (28.2%			1,176 (40.0%			1,482 (25.4%			3,695 (29.7%		0.08
3 - South; n (%)		221 (37.0%)		914 (31.1%)			2,336 (40.1%			4,602 (37.0%		0.00
4 - West; n (%)	925 (25.1%)	131 (21.9%)	0.08	420 (14.3%)	49 (11.4%)	0.09	988 (16.9%)	147 (15.6%)	0.04	2,333 (18.7%	327 (16.6%)	0.06
Race												
White; n (%)	2,727 (74.1%		-0.02				4,818 (82.7%			7,545 (60.6%		-0.06
Asian; n (%)	75 (2.0%)	11 (1.8%)	0.01				85 (1.5%)	>11	0.06	,	19 (1.0%)	0.03
Black; n (%)	346 (9.4%)	62 (10.4%)	-0.03					86 (9.1%)		974 (7.8%)	148 (7.5%)	0.01
Hispanic; n (%)	228 (6.2%)	39 (6.5%)	-0.01				135 (2.3%)	>11	0.09		49 (2.5%)	0.02
North American Native; n (%)							28 (0.5%)	>11		28 (0.5%)	4 (0.4%)	0.01
Other; n (%)							108 (1.9%)	16 (1.7%)	0.02	108 (1.9%)	16 (1.7%)	0.02
Cardiovascular event prognosticators					(()		//				//	
Acute or Old MI; n (%)	1,428 (38.8%	232 (38.9%)	0.00	, ,	97 (22.5%)		2,039 (35.0%		-0.05			-0.02
Anxiety; n (%)	228 (6.2%)	37 (6.2%)	0.00	- (/	24 (5.6%)		399 (6.8%)	58 (6.2%)	0.02	- (/	119 (6.0%)	0.00
Atrial Fibrillation; n (%)	633 (17.2%)	101 (16.9%)	0.01	387 (13.2%)	73 (16.9%)		, ,	207 (22.0%)	-0.06	, ,		-0.05
Coronary Atherosclerosis; n (%)	2,781 (75.6%	475 (79.6%)	-0.10	2,116 (72.0%			4,790 (82.2%	776 (82.5%)	-0.01	-, (-0.04
Coronary, Carotid, Illiac, Femoral, and Popliteal Revascularization (Angioplasty/Stent/CABG); n	358 (9.7%)	50 (8.4%)	0.05	269 (9.2%)	35 (8.1%)		. ,	71 (7.5%)	0.10			0.07
Diabetes with Complications; n (%)	1,297 (35.2%	208 (34.8%)	0.01	357 (12.2%)	63 (14.6%)		4,642 (79.6%			6,296 (50.6%		-0.01
Diabetes without Complications; n (%)	747 (20.3%)	131 (21.9%)	-0.04	. ,	143 (33.2%)		2,203 (37.8%		0.00	, ,		-0.01
DVT; n (%)	150 (4.1%)	27 (4.5%)	-0.02	108 (3.7%)	6 (1.4%)		257 (4.4%)	43 (4.6%)	-0.01	515 (4.1%)	76 (3.9%)	0.01
Edema; n (%)	344 (9.3%)	68 (11.4%)	-0.07	178 (6.1%)	30 (7.0%)		. ,	138 (14.7%)	-0.07		236 (12.0%)	-0.06 -0.04
Erectile dysfunction; n (%)	455 (12.4%)	82 (13.7%)	-0.04	265 (9.0%)	44 (10.2%)		705 (12.1%)	123 (13.1%)	-0.03	, - ,	249 (12.6%)	
Foot ulcer; n (%)	90 (2.4%) 3,088 (83.9%	23 (3.9%) 511 (85.6%)	-0.09 -0.05	52 (1.8%)	10 (2.3%) 302 (70.1%)		262 (4.5%)	49 (5.2%)	-0.03 -0.02		82 (4.2%) 1,671 (84.9%	-0.05 -0.07
Hyperlipidemia; n (%)	3,188 (86.6%	522 (87.4%)	-0.03	1,865 (63.5% 2,192 (74.6%	331 (76.8%)		5,283 (90.6% 5,428 (93.1%	858 (91.2%) 880 (93.5%)	-0.02		1,733 (88.0%	-0.07
Hypertension; n (%) Intracranial or Retroperitoneal Hemorrhage; n (%)	54 (1.5%)	5 (0.8%)	0.02	20 (0.7%)	5 (1.2%)		92 (1.6%)	>11	-0.02		27 (1.4%)	-0.04
Ischemic Heart Disease; n (%)	3,026 (82.2%	504 (84.4%)	-0.06		, ,		, ,	806 (85.7%)	0.02	,	, ,	-0.01
Ischemic Stroke; n (%)	644 (17.5%)	119 (19.9%)	-0.06	497 (16.9%)	79 (18.3%)		1,510 (25.9%	232 (24.7%)	0.00	2,651 (21.3%		-0.02
Major Trauma; n (%)	196 (5.3%)	30 (5.0%)	0.01		21 (4.9%)		, ,	56 (6.0%)	0.03		107 (5.4%)	0.02
Obesity; n (%)	524 (14.2%)	68 (11.4%)	0.01		47 (10.9%)			164 (17.4%)	-0.02			0.00
Other Disorders of Thyroid Gland; n (%)	112 (3.0%)	18 (3.0%)		69 (2.3%)	13 (3.0%)		. ,	38 (4.0%)		443 (3.6%)	69 (3.5%)	0.00
Overweight; n (%)	294 (8.0%)	46 (7.7%)	0.00	83 (2.8%)	13 (3.0%)			42 (4.5%)	-0.05		101 (5.1%)	-0.02
PE; n (%)	59 (1.6%)	10 (1.7%)	-0.01	39 (1.3%)	2 (0.5%)			14 (1.5%)	0.02	197 (1.6%)	26 (1.3%)	0.03
Peripheral Vascular Disease; n (%)		205 (34.3%)	-0.01		117 (27.1%)		1,798 (30.8%		0.02			-0.01
Stable Angina; n (%)	490 (13.3%)	83 (13.9%)	-0.02	276 (9.4%)	37 (8.6%)			115 (12.2%)	0.03			0.01
Systemic Embolism; n (%)	60 (1.6%)	11 (1.8%)	-0.02	49 (1.7%)	10 (2.3%)		109 (1.9%)	>113 (12.270)	0.03	,	31 (1.6%)	0.01
TIA; n (%)	90 (2.4%)	22 (3.7%)		63 (2.1%)	10 (2.3%)			36 (3.8%)		419 (3.4%)	68 (3.5%)	-0.01
General Health/Mortality Prognosticators	55 (2.770)	22 (3.770)	0.08	00 (2.170)	10 (2.370)	3.01	200 (4.070)	33 (3.070)	0.04	.25 (5.470)	00 (0.070)	-0.01
Abnormal liver function; n (%)	333 (9.0%)	55 (9.2%)	-0.01	189 (6.4%)	28 (6.5%)	0.00	574 (9.8%)	97 (10.3%)	-0.02	1,096 (8.8%)	180 (9 1%)	-0.01
Alcohol Abuse/Dependence; n (%)	72 (2.0%)	17 (2.8%)	-0.01		5 (1.2%)			19 (2.0%)	-0.02		41 (2.1%)	-0.01
Anemias (Sickle-Cell, G6PD Deficiency, Nutrient Deficiency); n (%)	840 (22.8%)	157 (26.3%)	-0.03		72 (16.7%)			286 (30.4%)	0.01			0.03
Asthma; n (%)	150 (4.1%)	22 (3.7%)	0.02	. ,	22 (5.1%)		, ,	58 (6.2%)	-0.01	-, (102 (5.2%)	-0.01
COPD; n (%)	859 (23.3%)	137 (22.9%)	0.02		79 (18.3%)		1,421 (24.4%			2,782 (22.3%		0.00
Delirium; n (%)	69 (1.9%)	16 (2.7%)		50 (1.7%)	5 (1.2%)		, ,	36 (3.8%)		296 (2.4%)	57 (2.9%)	-0.03
5 Carrison (1 (14)	JJ (1.J/0)	10 (2.7 /0)	-0.03	JJ (1.770)	~ (1.4/0)	0.04	-11 (3.070)	50 (5.070)	-0.04	-30 (2.4/0)	31 (2.3/0)	-0.03

Table 1: Unmatched

Dementia; n (%)	101 (2.7%)	18 (3.0%)		56 (1.9%)	10 (2.3%)		222 (3.8%)	31 (3.3%)	0.03		59 (3.0%)	0.00
Depression ; n (%)	318 (8.6%)	48 (8.0%)		157 (5.3%)	25 (5.8%)		561 (9.6%)	77 (8.2%)	0.05	1,036 (8.3%)	150 (7.6%)	0.03
Falls; n (%)	229 (6.2%)	42 (7.0%)	-0.03	68 (2.3%)	13 (3.0%)	-0.04	351 (6.0%)	72 (7.7%)	-0.07	648 (5.2%)	127 (6.4%)	-0.05
Fractures; n (%)	226 (6.1%)	32 (5.4%)	0.03	147 (5.0%)	22 (5.1%)	0.00	341 (5.9%)	47 (5.0%)	0.04	714 (5.7%)	101 (5.1%)	0.03
HIV/AIDS; n (%)	6 (0.2%)	2 (0.3%)	-0.02	1 (0.0%)	0 (0.0%)		>11	>11	-0.04	14 (0.1%)	5 (0.3%)	-0.04
Organ Transplant; n (%)	16 (0.4%)	5 (0.8%)	-0.05	20 (0.7%)	4 (0.9%)	-0.02	45 (0.8%)	>11	0.04		14 (0.7%)	0.00
Osteoporosis; n (%)	201 (5.5%)	27 (4.5%)		134 (4.6%)	14 (3.2%)		399 (6.8%)	56 (6.0%)	0.03		97 (4.9%)	0.04
Peptic Ulcer Disease; n (%)	892 (24.2%)	154 (25.8%)		437 (14.9%)	80 (18.6%)			259 (27.5%)	0.00			-0.04
	72 (2.0%)										53 (2.7%)	-0.04
Pneumonia; n (%)	_ ' '	17 (2.8%)		134 (4.6%)	17 (3.9%)		108 (1.9%)	19 (2.0%)		314 (2.5%)		
Renal Failure; n (%)	775 (21.1%)	142 (23.8%)		393 (13.4%)	57 (13.2%)		1,467 (25.2%		-0.04	, ,		-0.04
Renal Failure (CKD Stage 4 or higher); n (%)	128 (3.5%)	20 (3.4%)	0.01		12 (2.8%)		311 (5.3%)	50 (5.3%)	0.00		82 (4.2%)	0.00
Sleep Apnea; n (%)	432 (11.7%)	57 (9.5%)	0.07	317 (10.8%)	44 (10.2%)	0.02	741 (12.7%)	109 (11.6%)	0.03	1,490 (12.0%	210 (10.7%)	0.04
Sleep Disorder; n (%)	295 (8.0%)	29 (4.9%)	0.13	307 (10.4%)	39 (9.0%)	0.05	760 (13.0%)	104 (11.1%)	0.06	1,362 (10.9%	172 (8.7%)	0.07
Smoking; n (%)	1,015 (27.6%	194 (32.5%)	-0.11	352 (12.0%)	71 (16.5%)	-0.13	1,758 (30.2%	296 (31.5%)	-0.03	3,125 (25.1%	561 (28.5%)	-0.08
Frailty Score: Empirical Version 365 days (ICD-9 and ICD-10) v2												
mean (sd)	0.17 (0.05)	0.17 (0.05)	0.00	0.16 (0.05)	0.16 (0.05)	0.00	0.20 (0.06)	0.19 (0.06)	0.17	0.18 (0.05)	0.18 (0.06)	0.00
median [IQR]		0.16 [0.13, 0		0.15 [0.13, 0.			0.19 [0.16, 0.			0.17 (0.06)	0.17 (0.06)	0.00
Healthcare utilization			1	()	(0)		(0)	(0)		(0.00)	(0.00)	
	905 (24.6%)	155 (26.0%)	-0.03	786 (26.8%)	95 (22 0%)	0.11	1,691 (29.0%	250 (26.6%)	0.05	3,382 (27.2%	500 (25.4%)	0.04
Any hospitalization; n (%)												0.04
Bone mineral density; n (%)	162 (4.4%)	23 (3.9%)	0.03		10 (2.3%)		245 (4.2%)	43 (4.6%)	-0.02		76 (3.9%)	
BUN tests; n (%)	502 (13.6%)	89 (14.9%)	-0.04	281 (9.6%)	48 (11.1%)	-0.05	1,151 (19.7%	184 (19.6%)	0.00	1,934 (15.5%	321 (16.3%)	-0.02
Cardiologist visit	1		ļ	ļ								
0	1,492 (40.5%	205 (34.3%)	0.13	1,317 (44.8%	193 (44.8%)	0.00	1,338 (23.0%	195 (20.7%)	0.06	4,147 (33.3%	593 (30.1%)	0.07
1-2	1,101 (29.9%	175 (29.3%)	0.01	744 (25.3%)	115 (26.7%)	-0.03	1,920 (32.9%	325 (34.5%)	-0.03	3,765 (30.2%	615 (31.2%)	-0.02
3-5	665 (18.1%)	146 (24.5%)	-0.16	536 (18.2%)	76 (17.6%)	0.02	1,567 (26.9%	254 (27.0%)	0.00	2,768 (22.2%	476 (24.2%)	-0.05
>=6	423 (11.5%)	71 (11.9%)	-0.01				1,004 (17.2%		-0.01		285 (14.5%)	-0.01
Colonoscopy; n (%)	412 (11.2%)	69 (11.6%)	-0.01		43 (10.0%)		632 (10.8%)	109 (11.6%)	-0.03	, ,		-0.01
Endocrinologist Visit; n (%)	178 (4.8%)	20 (3.4%)	0.07		15 (3.5%)		563 (9.7%)	93 (9.9%)	-0.01		128 (6.5%)	0.00
	300 (8.1%)	52 (8.7%)		127 (4.3%)			401 (6.9%)	64 (6.8%)	0.00			-0.01
Fecal occult blood (FOB) test; n (%)					20 (4.6%)						136 (6.9%)	
Flu vaccine; n (%)		218 (36.5%)		588 (20.0%)	82 (19.0%)			617 (65.6%)	-0.12	, ,		-0.06
Glucose test strips; n (%)	86 (2.3%)	14 (2.3%)		45 (1.5%)	8 (1.9%)		357 (6.1%)	63 (6.7%)	-0.02		85 (4.3%)	-0.02
Glucose tests; n (%)	578 (15.7%)	101 (16.9%)	-0.03	336 (11.4%)	59 (13.7%)	-0.07	1,837 (31.5%	276 (29.3%)	0.05	2,751 (22.1%	436 (22.1%)	0.00
- · · · · · · · · · · · · · · · · · · ·												
HbA1c tests ; n (%)		280 (46.9%)		570 (19.4%)			4,510 (77.4%			6,634 (53.3%		-0.05
HbA1c tests ; n (%)	1,554 (42.2%			570 (19.4%)	97 (22.5%)	-0.08		724 (76.9%)		6,634 (53.3%	1,101 (55.9%)	
HbA1c tests ; n (%)	1,554 (42.2%	280 (46.9%)	-0.09	570 (19.4%) 1,366 (46.5%	97 (22.5%)	-0.08 0.33	4,510 (77.4% 2,879 (49.4%	724 (76.9%) 355 (37.7%)	0.01	6,634 (53.3% 5,962 (47.9%	1,101 (55.9%) 684 (34.7%)	-0.05 0.27
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0	1,554 (42.2%) 1,717 (46.6%) 1,620 (44.0%)	280 (46.9%) 197 (33.0%) 323 (54.1%)	-0.09 0.28 -0.20	570 (19.4%) 1,366 (46.5% 1,243 (42.3%	97 (22.5%) 132 (30.6%) 217 (50.3%)	-0.08 0.33 -0.16	4,510 (77.4% 2,879 (49.4% 2,248 (38.6%	724 (76.9%) 355 (37.7%) 438 (46.5%)	0.01 0.24 -0.16	5,962 (47.9% 5,111 (41.1%	1,101 (55.9%) 684 (34.7%) 978 (49.7%)	-0.05 0.27 -0.17
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%)	-0.09 0.28 -0.20 -0.11	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%)	-0.08 0.33 -0.16 -0.22	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%)	0.01 0.24 -0.16 -0.11	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0%	1,101 (55.9%) 684 (34.7%) 978 (49.7%) 307 (15.6%)	-0.05 0.27 -0.17 -0.14
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%)	1,554 (42.2%) 1,717 (46.6%) 1,620 (44.0%) 344 (9.3%) 3,489 (94.8%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%)	-0.09 0.28 -0.20 -0.11 -0.01	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5%	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%)	-0.08 0.33 -0.16 -0.22 -0.06	2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5%	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%)	0.01 0.24 -0.16 -0.11 0.01	5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1)	1,101 (55.9%) 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6%)	-0.05 0.27 -0.17 -0.14 -0.02
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%)	1,554 (42.2%) 1,717 (46.6%) 1,620 (44.0%) 344 (9.3%) 3,489 (94.8%) 2,689 (73.1%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%)	-0.09 0.28 -0.20 -0.11 -0.01 -0.01	1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4%	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0%	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%)	0.01 0.24 -0.16 -0.11 0.01 0.06	5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1° 8,713 (70.0%	1,101 (55.9%) 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6%) 1,380 (70.1%)	-0.05 0.27 -0.17 -0.14 -0.02 0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%)	1,554 (42.2%) 1,717 (46.6%) 1,620 (44.0%) 344 (9.3%) 3,489 (94.8%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%)	-0.09 0.28 -0.20 -0.11 -0.01 -0.01	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5%	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02	2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5%	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%)	0.01 0.24 -0.16 -0.11 0.01 0.06	5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1)	1,101 (55.9%) 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6%) 1,380 (70.1%)	-0.05 0.27 -0.17 -0.14 -0.02
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptions	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%)	-0.09 0.28 -0.20 -0.11 -0.01 -0.01 0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7%	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07	5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1) 8,713 (70.0% 3,753 (30.1%	1,101 (55.9%) 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6%) 1,380 (70.1%) 647 (32.9%)	-0.05 0.27 -0.17 -0.14 -0.02 0.00 -0.06
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%)	1,554 (42.2%) 1,717 (46.6%) 1,620 (44.0%) 344 (9.3%) 3,489 (94.8%) 2,689 (73.1%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%)	-0.09 0.28 -0.20 -0.11 -0.01 -0.01 0.00	1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4%	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07	5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60)	1,101 (55.9%) 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6%) 1,380 (70.1%) 647 (32.9%)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptions	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%)	-0.09 0.28 -0.20 -0.11 -0.01 0.00 -0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 152 (35.3%) 72 (16.7%) 10.55 (5.10)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7%	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07	5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1) 8,713 (70.0% 3,753 (30.1%	1,101 (55.9%) 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6%) 1,380 (70.1%) 647 (32.9%)	-0.05 0.27 -0.17 -0.14 -0.02 0.00 -0.06
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Mumber of different/distinct medication prescriptionsmean (sd)median [IQR]	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02)	-0.09 0.28 -0.20 -0.11 -0.01 0.00 -0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3%) 329 (11.2%) 2,513 (85.5%) 1,011 (34.4%) 404 (13.8%) 10.22 (5.52)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 152 (35.3%) 72 (16.7%) 10.55 (5.10)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07	5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6%) 1,380 (70.1%) 647 (32.9%) 10.40 (5.31)	-0.05 0.27 -0.17 -0.14 -0.02 0.00 -0.06
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)	1,554 (42.2% 1,717 (46.6% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 1;	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02)	-0.09 0.28 -0.20 -0.11 -0.01 0.00 0.00 -0.04	570 (19.4%) 1,366 (46.5% 1,243 (42.3%) 329 (11.2%) 2,513 (85.5%) 1,011 (34.4%) 404 (13.8%) 10.22 (5.52)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 10.00 [7.00, 1	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.08	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00	5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91)	-0.05 0.27 -0.17 -0.14 -0.02 0.00 -0.06
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1%) 921 (25.0%) 8.01 (6.17) 8.00 (3.00, 1:	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1] 12.44 (6.38)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.04 -0.04 -0.00 -0.00	570 (19.4%) 1,366 (46.5%) 1,243 (42.3%) 329 (11.2%) 2,513 (85.5%) 1,011 (34.4%) 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 13] 12.31 (7.03)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 10.00 [7.00, 1	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.08 -0.09 -0.09 -0.09	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 [8.00, 1	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)median [IQR]	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1%) 921 (25.0%) 8.01 (6.17) 8.00 (3.00, 1:	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1]	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.04 -0.04 -0.00 -0.00	570 (19.4%) 1,366 (46.5%) 1,243 (42.3%) 329 (11.2%) 2,513 (85.5%) 1,011 (34.4%) 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 13]	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 10.00 [7.00, 1	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.08 -0.09 -0.09 -0.09	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 [8.00, 1	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)	1,554 (42.2% 1,717 (46.6% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 (3.00, 1: 12.48 (6.80) 11.00 [8.00, 4:	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.04 -0.04 -0.04 -0.04 -0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, 5]	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 10.00 (7.00, 1 12.46 (6.32) 11.00 (8.00, 1	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.06 -0.19 -0.00	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 [8.00, 1	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 0.05	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38)	-0.05 0.27 -0.17 -0.14 -0.02 0.00 -0.06 -0.01 -0.04 0.02 0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1%) 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 12] 12.48 (6.80) 11.00 [8.00, 20]	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 28.00 [4.00, 1] 12.44 (6.38) 11.00 [8.00, 409 (68.5%)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.00 -0.04 2 0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4%) 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 13.6] 11.00 [8.00, 13.6]	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 11.00 (7.00, 1) 12.46 (6.32) 11.00 [8.00, 1)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.09 -0.09 -0.09 -0.00 0.00	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00, 1 14.62 (7.67) 13.00 (9.00, 1	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1° 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2%	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1%) 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6%)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.02 -0.00 -0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1%) 8.01 (6.17) 8.00 (3.00, 1: 12.48 (6.80) 11.00 (8.00, 4.6) 2,571 (69.8% 455 (12.4%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.04 -0.04 -0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, : 2,668 (90.8% 112 (3.8%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 10.55 (5.10) 10.00 [7.00, 1 12.46 (6.32) 11.00 [8.00, 1 390 (90.5%) 16 (3.7%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.08 -0.09 -0.00 0.01 0.01	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 [8.00, 1 14.62 (7.67) 13.00 [9.00, 1 3,246 (55.7% 1,059 (18.2%	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 552 (58.7%) 185 (19.7%)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.00	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1%	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.02 -0.00 -0.00 -0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 12] 12.48 (6.80) 11.00 [8.00, 20] 455 (12.4%) 655 (17.8%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 558 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.04 -0.04 -0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, 2,668 (90.8% 112 (3.8%) 158 (5.4%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.00 (7.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.06 -0.19 -0.02 0.00 0.01 -0.01 -0.01 -0.01	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00, 1 14.62 (7.67) 13.00 [9.00, 1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1%	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.00 (8.00, 1 14.29 (6.95) 13.00 [9.00, 1 552 (58.7%) 185 (19.7%) 204 (21.7%)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.00 -0.04 -0.06 -0.04	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8%	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1%) 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.02 -0.00 -0.00 -0.00 -0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%)	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1%) 8.01 (6.17) 8.00 (3.00, 1: 12.48 (6.80) 11.00 (8.00, 4.6) 2,571 (69.8% 455 (12.4%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.04 -0.04 -0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, : 2,668 (90.8% 112 (3.8%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 10.55 (5.10) 10.00 [7.00, 1 12.46 (6.32) 11.00 [8.00, 1 390 (90.5%) 16 (3.7%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.06 -0.19 -0.02 0.00 0.01 -0.01 -0.01 -0.01	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 [8.00, 1 14.62 (7.67) 13.00 [9.00, 1 3,246 (55.7% 1,059 (18.2%	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.00 (8.00, 1 14.29 (6.95) 13.00 [9.00, 1 552 (58.7%) 185 (19.7%) 204 (21.7%)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.00 -0.04 -0.06 -0.04	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1%	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1%) 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.02 -0.00 -0.00 -0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)meain [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1%) 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 1: 12.48 (6.80) 11.00 [8.00, : 2,571 (69.8% 455 (12.4%) 655 (17.8%) 958 (26.0%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 28.00 [4.00, 1] 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.04 2	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4%) 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 (8.00, : 2,668 (90.8% 112 (3.8%) 158 (5.4%) 276 (9.4%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 10.00 (7.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.19 -0.02 0.00 0.01 0.01 -0.02 -0.07	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00,1 14.62 (7.67) 13.00 (9.00,1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8%)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 552 (58.7%) 185 (19.7%) 204 (21.7%) 281 (29.9%)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1° 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5%	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.02 -0.00 -0.01 -0.03 -0.04 -0.11
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%)	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 12] 12.48 (6.80) 11.00 [8.00, 20] 455 (12.4%) 655 (17.8%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 558 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.04 2	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, 2,668 (90.8% 112 (3.8%) 158 (5.4%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.00 (7.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.19 -0.02 0.00 0.01 0.01 -0.02 -0.07	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00, 1 14.62 (7.67) 13.00 [9.00, 1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1%	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.00 (8.00, 1 14.29 (6.95) 13.00 [9.00, 1 552 (58.7%) 185 (19.7%) 204 (21.7%)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8%	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1%) 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%)	-0.05 0.27 -0.17 -0.14 -0.02 0.00 -0.06 -0.01 -0.04 0.02 0.00 -0.01 -0.01 -0.03 0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)meain [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1%) 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 1: 12.48 (6.80) 11.00 [8.00, : 2,571 (69.8% 455 (12.4%) 655 (17.8%) 958 (26.0%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 28.00 [4.00, 1] 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.04 2	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4%) 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 (8.00, : 2,668 (90.8% 112 (3.8%) 158 (5.4%) 276 (9.4%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 10.00 (7.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.19 -0.02 0.00 0.01 0.01 -0.02 -0.07	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00,1 14.62 (7.67) 13.00 (9.00,1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8%)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 552 (58.7%) 185 (19.7%) 204 (21.7%) 281 (29.9%)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1° 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5%	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.02 -0.00 -0.01 -0.03 -0.04 -0.11
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Test	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1%) 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 1: 12.48 (6.80) 11.00 [8.00, : 2,571 (69.8% 455 (12.4%) 655 (17.8%) 958 (26.0%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 28.00 [4.00, 1] 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.04 -0.04 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.02	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4%) 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 (8.00, : 2,668 (90.8% 112 (3.8%) 158 (5.4%) 276 (9.4%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 10.00 (7.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.06 -0.19 -0.02 -0.00 0.01 -0.01 -0.02 -0.07	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00,1 14.62 (7.67) 13.00 (9.00,1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8%)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 552 (58.7%) 185 (19.7%) 204 (21.7%) 281 (29.9%)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.02 -0.00 -0.01 -0.03 -0.04 -0.01
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)	1,554 (42.2% 1,717 (46.6% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 1: 12.48 (6.80) 11.00 [8.00, 2,571 (69.8% 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%) 1 (0.2%) 2.40 (1.74)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.04 -0.04 -0.04 -0.01 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.05	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, : 2,668 (90.8% 112 (3.8%) 158 (5.4%) 276 (9.4%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.00 (7.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.09 -0.09 0.01 0.01 -0.02 -0.00 0.01 0.01 -0.02 -0.07 -0.06	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00, 1 14.62 (7.67) 13.00 [9.00, 1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8%)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.00 (8.00, 1 14.29 (6.95) 13.00 (9.00, 1 552 (58.7%) 185 (19.7%) 204 (21.7%) 281 (29.9%) >11	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%)	-0.05 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.02 -0.00 -0.01 -0.01 -0.03 -0.04 -0.01 -0.00 -0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)median [IQR] median [IQR]	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1%) 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 1: 12.48 (6.80) 11.00 [8.00, : 2,571 (69.8% 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%) 2,42 (1.78) 2,00 [1.00, 3.	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 28.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 11 (18.6%) 18 (30.7%) 1 (0.2%) 2.40 (1.74) 2.00 [1.00, 3	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.04 -0.04 -0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.05 -0.05	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 (8.00, : 2,668 (90.8% 112 (3.8%) 158 (5.4%) 7 (0.2%) 1.19 (3.39) 0.00 [0.00, 2.	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 10.00 (7.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%) 0 (0.0%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.19 -0.02 0.00 0.01 -0.01 -0.02 -0.07 -0.06	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 [8.00, 1 14.62 (7.67) 13.00 [9.00, 1 3,246 (55.7% 1,059 (18.2% 1,445 (24.8%) 28 (0.5%) 2.59 (1.58) 2.00 [2.00, 3.	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 425 (45.2%) 11.00 [8.00, 1 11.00 [8.00, 1 13.00 [9.00, 1 152 (58.7%) 185 (19.7%) 204 (21.7%) 211 2.41 (1.43) 2.00 [1.00, 3.	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11 -0.03	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1° 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%) 2.21 (2.20) 1.53 (2.74)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%) 2.10 (1.55) 1.56 (1.73)	-0.05 -0.27 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.02 -0.03 -0.04 -0.11 -0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)median [IQR] Prostatectomy; n (%)	1,554 (42.2% 1,717 (46.6% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 1: 12.48 (6.80) 11.00 [8.00, 2,571 (69.8% 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%) 1 (0.2%) 2.40 (1.74)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.04 -0.04 -0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.05 -0.05	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, 2,668 (90.8% 112 (3.8%) 158 (5.4%) 27 (0.2%) 1.19 (3.39)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 10.00 (7.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%) 0 (0.0%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.19 -0.02 0.00 0.01 -0.01 -0.02 -0.07 -0.06	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00, 1 14.62 (7.67) 13.00 [9.00, 1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8%) 28 (0.5%)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.00 (8.00, 1 14.29 (6.95) 13.00 [9.00, 1 1552 (58.7%) 185 (19.7%) 281 (29.9%) >11 2.41 (1.43)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11 -0.03	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1%) 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6%) 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%) 2.10 (1.55)	-0.05 -0.17 -0.14 -0.02 -0.06 -0.01 -0.04 -0.02 -0.00 -0.01 -0.03 -0.04 -0.11 -0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)median [IQR] Prostatectomy; n (%) Prostate exam for DRE	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 1: 12.48 (6.80) 11.00 [8.00, : 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%) 2.42 (1.78) 2.00 [1.00, 3. 146 (4.0%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 558 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%) 2.40 (1.74) 2.00 [1.00, 3 18 (3.0%)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.04 -0.04 -0.01 -0.01 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.02 -0.05	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, : 2,668 (90.8% 112 (3.8%) 158 (5.4%) 276 (9.4%) 7 (0.2%) 1.19 (3.39) 0.00 [0.00, 2. 117 (4.0%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.05 (5.10) 11.00 (8.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%) 0 (0.0%) 1.00 (1.51) 0.00 (0.00, 2.1 11 (2.6%)	-0.08 -0.16 -0.22 -0.06 -0.02 -0.08 -0.06 -0.19 -0.02 -0.00 -0.01 -0.01 -0.02 -0.07 -0.06 -0.12 -0.00 -0.08	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00, 1 14.62 (7.67) 13.00 (9.00, 1 1,524 (26.1% 1,445 (24.8% 28 (0.5%) 2.59 (1.58) 2.00 (2.00, 3.132 (2.3%)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 185 (19.7%) 204 (21.7%) 281 (29.9%) >11 2.41 (1.43) 2.00 [1.00, 3. 22 (2.3%)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11 -0.03 0.12 -1.33 0.00	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1° 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%) 2.21 (2.20) 1.53 (2.74)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%) 2.10 (1.55) 1.56 (1.73)	-0.05 -0.17 -0.14 -0.02 -0.06 -0.01 -0.04 -0.02 -0.00 -0.01 -0.03 -0.04 -0.11 -0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 =4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 =6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR] Prostate exam for DREmean (sd)	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 1: 12.48 (6.80) 11.00 [8.00, : 2,571 (69.8% 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%) 2.42 (1.78) 2.00 [1.00, 3.146 (4.0%) 1.19 (3.27)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 2.800 (4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%) 2.40 (1.74) 2.00 [1.00, 3 18 (3.0%) 1.18 (2.90)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.00 -0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.05 -0.05 -0.05 -0.00 -0.05 -0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, 1: 2,668 (90.8% 112 (3.8%) 158 (5.4%) 7 (0.2%) 1.19 (3.39) 0.00 [0.00, 2. 117 (4.0%) 0.31 (1.48)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 11.00 (7.00, 1 12.46 (6.32) 11.00 [8.00, 1 1390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%) 0 (0.0%) 1.00 (1.51) 0.00 [0.00, 2. 11 (2.6%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.09 -0.09 -0.01 0.01 -0.02 -0.07 -0.06 0.12 0.00 0.08	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 [8.00, 1] 14.62 (7.67) 13.00 [9.00, 1] 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8%) 28 (0.5%) 2.59 (1.58) 2.00 [2.00, 3.132 (2.3%) 0.38 (0.81)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 1552 (58.7%) 185 (19.7%) 204 (21.7%) 211 2.41 (1.43) 2.00 [1.00, 3. 22 (2.3%) 0.42 (0.82)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11 -0.03 0.12 -1.33 0.00	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1° 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%) 2.21 (2.20) 1.53 (2.74)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%) 2.10 (1.55) 1.56 (1.73)	-0.05 -0.17 -0.14 -0.02 -0.06 -0.01 -0.04 -0.03 -0.03 -0.04 -0.11 -0.06 -0.06 -0.06 -0.06 -0.07 -0.07 -0.08 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR]	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 [3.00, 1: 12.48 (6.80) 11.00 [8.00, : 2,571 (69.8% 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%) 2.42 (1.78) 2.00 [1.00, 3.146 (4.0%) 1.19 (3.27)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 558 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%) 2.40 (1.74) 2.00 [1.00, 3 18 (3.0%)	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.00 -0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.05 -0.05 -0.05 -0.00 -0.05 -0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, : 2,668 (90.8% 112 (3.8%) 158 (5.4%) 276 (9.4%) 7 (0.2%) 1.19 (3.39) 0.00 [0.00, 2. 117 (4.0%)	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.55 (5.10) 11.00 (7.00, 1 12.46 (6.32) 11.00 [8.00, 1 1390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%) 0 (0.0%) 1.00 (1.51) 0.00 [0.00, 2. 11 (2.6%)	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.09 -0.09 -0.01 0.01 -0.02 -0.07 -0.06 0.12 0.00 0.08	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00, 1 14.62 (7.67) 13.00 (9.00, 1 1,524 (26.1% 1,445 (24.8% 28 (0.5%) 2.59 (1.58) 2.00 (2.00, 3.132 (2.3%)	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 1552 (58.7%) 185 (19.7%) 204 (21.7%) 211 2.41 (1.43) 2.00 [1.00, 3. 22 (2.3%) 0.42 (0.82)	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11 -0.03 0.12 -1.33 0.00	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1° 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%) 2.21 (2.20) 1.53 (2.74)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%) 2.10 (1.55) 1.56 (1.73)	-0.05 -0.17 -0.14 -0.02 -0.06 -0.01 -0.04 -0.03 -0.03 -0.04 -0.11 -0.06 -0.06 -0.06 -0.06 -0.07 -0.07 -0.08 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09 -0.09
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR] Prostate Cancer Comorbidity Index (PCCI)	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 8.01 (6.17) 8.00 [3.00, 1: 12.48 (6.80) 11.00 [8.00, : 2,571 (69.8% 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%) 2.42 (1.78) 2.00 [1.00, 3. 146 (4.0%)	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%) 1 (0.2%) 2.40 (1.74) 2.00 [1.00, 3 18 (3.0%) 1.18 (2.90) 0.00 [0.00, 0	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.00 -0.04 -0.04 -0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.02 -0.02 -0.02 -0.10 -0.05 -0.05 -0.00 -0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, : 2,668 (90.8% 112 (3.8%) 158 (5.4%) 276 (9.4%) 7 (0.2%) 1.19 (3.39) 0.00 [0.00, 2, 117 (4.0%) 0.31 (1.48) 0.00 [0.00, 0, 0.00 [0.00, 0, 0.00]	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 10.05 (5.10) 10.00 [7.00, 1 1.00 [8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%) 0 (0.0%) 1.00 (1.51) 0.00 [0.00, 2.4 11 (2.6%) 0.00 [0.00, 0.4	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.09 -0.00 0.01 -0.01 -0.02 -0.07 -0.06 -0.19 -0.07 -0.07 -0.06 -0.11 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 11.92 (5.24) 11.00 [8.00, 1 14.62 (7.67) 13.00 [9.00, 1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8% 28 (0.5%) 2.59 (1.58) 2.00 [2.00, 3. 132 (2.3%) 0.38 (0.81) 0.00 [0.00, 0.	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.69 (4.90) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 1552 (58.7%) 185 (19.7%) 204 (21.7%) 281 (29.9%) >11 2.41 (1.43) 2.00 [1.00, 3. 22 (2.3%) 0.00 [0.00, 1.	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 -0.11 -0.11 -0.03 0.12 -1.33 -0.00 -0.05 -0.00	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%) 2.21 (2.20) 1.53 (2.74) 395 (3.2%)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%) 2.10 (1.55) 1.56 (1.73) 51 (2.6%)	-0.05 -0.17 -0.14 -0.02 -0.06 -0.01 -0.04 -0.02 -0.05 -0.01 -0.04 -0.01 -0.04 -0.01 -0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR]	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 (3.00, 1: 12.48 (6.80) 11.00 (8.00, 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%) 2.42 (1.78) 2.00 (1.00, 3. 146 (4.0%) 1.19 (3.27) 0.00 (0.00, 0.	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 558 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%) 2.40 (1.74) 2.00 [1.00, 3 18 (3.0%) 1.18 (2.90) 0.00 [0.00, 0	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.04 -0.04 -0.00 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.02 -0.05 -0.05 -0.05 -0.05 -0.00 -0.05 -0.00 -0.01 -0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 11.0	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.05 (5.10) 11.00 (8.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%) 0 (0.0%) 1.00 (1.51) 0.00 (0.00, 2.1 11 (2.6%) 0.31 (1.42) 0.00 (0.00, 0.0	-0.08 -0.16 -0.22 -0.06 -0.02 -0.08 -0.06 -0.19 -0.02 -0.00 -0.01 -0.01 -0.02 -0.07 -0.06 -0.12 -0.00 -0.08 -0.12 -0.00 -0.01	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00, 1 14.62 (7.67) 13.00 (9.00, 1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8% 28 (0.5%) 2.59 (1.58) 2.00 [2.00, 3. 132 (2.3%) 0.38 (0.81) 0.00 [0.00, 0.	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 185 (19.7%) 204 (21.7%) 281 (29.9%) >11 2.41 (1.43) 2.00 [1.00, 3. 22 (2.3%) 0.42 (0.82) 0.00 [0.00, 1.	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 -0.10 -0.11 -0.03 0.12 -1.33 0.00 -0.05 -0.00 -0.05 -0.00 -0.05 -0.00 -0.01 -0.01 -0.01	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%) 2.21 (2.20) 1.53 (2.74) 395 (3.2%) 35.44 (5.78)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%) 2.10 (1.55) 1.56 (1.73) 51 (2.6%) 36.38 (6.16)	-0.05 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.01 -0.03 -0.01 -0.03 -0.04 -0.01 -0.04 -0.01 -0.04
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR] Prostate Cancer Comorbidity Index (PCCI)	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 (3.00, 1: 12.48 (6.80) 11.00 (8.00, 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%) 2.42 (1.78) 2.00 (1.00, 3. 146 (4.0%) 1.19 (3.27) 0.00 (0.00, 0.	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 568 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%) 1 (0.2%) 2.40 (1.74) 2.00 [1.00, 3 18 (3.0%) 1.18 (2.90) 0.00 [0.00, 0	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.04 -0.04 -0.00 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.02 -0.05 -0.05 -0.05 -0.05 -0.00 -0.05 -0.00 -0.01 -0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, : 2,668 (90.8% 112 (3.8%) 158 (5.4%) 276 (9.4%) 7 (0.2%) 1.19 (3.39) 0.00 [0.00, 2, 117 (4.0%) 0.31 (1.48) 0.00 [0.00, 0, 0.00 [0.00, 0, 0.00]	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.05 (5.10) 11.00 (8.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%) 0 (0.0%) 1.00 (1.51) 0.00 (0.00, 2.1 11 (2.6%) 0.31 (1.42) 0.00 (0.00, 0.0	-0.08 -0.16 -0.22 -0.06 -0.02 -0.08 -0.06 -0.19 -0.02 -0.00 -0.01 -0.01 -0.02 -0.07 -0.06 -0.12 -0.00 -0.08 -0.12 -0.00 -0.01	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 11.92 (5.24) 11.00 [8.00, 1 14.62 (7.67) 13.00 [9.00, 1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8% 28 (0.5%) 2.59 (1.58) 2.00 [2.00, 3. 132 (2.3%) 0.38 (0.81) 0.00 [0.00, 0.	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 185 (19.7%) 204 (21.7%) 281 (29.9%) >11 2.41 (1.43) 2.00 [1.00, 3. 22 (2.3%) 0.42 (0.82) 0.00 [0.00, 1.	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 -0.10 -0.11 -0.03 0.12 -1.33 0.00 -0.05 -0.00 -0.05 -0.00 -0.05 -0.00 -0.01 -0.01 -0.01	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%) 2.21 (2.20) 1.53 (2.74) 395 (3.2%)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%) 2.10 (1.55) 1.56 (1.73) 51 (2.6%) 36.38 (6.16)	-0.05 -0.17 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.01 -0.04 -0.01 -0.03 -0.04 -0.11 -0.00
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)median [IQR] Prostatectomy; n (%) Prostate exam for DREmean (sd)median [IQR] Prostate cancer Comorbidity Index (PCCI)mean (sd)	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1% 921 (25.0%) 8.01 (6.17) 8.00 (3.00, 1: 12.48 (6.80) 11.00 (8.00, 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%) 2.42 (1.78) 2.00 (1.00, 3. 146 (4.0%) 1.19 (3.27) 0.00 (0.00, 0.	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 558 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%) 2.40 (1.74) 2.00 [1.00, 3 18 (3.0%) 1.18 (2.90) 0.00 [0.00, 0	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.04 -0.04 -0.00 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.02 -0.05 -0.05 -0.05 -0.05 -0.00 -0.05 -0.00 -0.01 -0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 11.0	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 72 (16.7%) 10.05 (5.10) 11.00 (8.00, 1 12.46 (6.32) 11.00 (8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%) 0 (0.0%) 1.00 (1.51) 0.00 (0.00, 2.1 11 (2.6%) 0.31 (1.42) 0.00 (0.00, 0.0	-0.08 -0.16 -0.22 -0.06 -0.02 -0.08 -0.06 -0.19 -0.02 -0.00 -0.01 -0.01 -0.02 -0.07 -0.06 -0.12 -0.00 -0.08 -0.12 -0.00 -0.01	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00, 1 14.62 (7.67) 13.00 (9.00, 1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8% 28 (0.5%) 2.59 (1.58) 2.00 [2.00, 3. 132 (2.3%) 0.38 (0.81) 0.00 [0.00, 0.	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 185 (19.7%) 204 (21.7%) 281 (29.9%) >11 2.41 (1.43) 2.00 [1.00, 3. 22 (2.3%) 0.42 (0.82) 0.00 [0.00, 1.	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 -0.10 -0.11 -0.03 0.12 -1.33 0.00 -0.05 -0.00 -0.05 -0.00 -0.05 -0.00 -0.01 -0.01 -0.01	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%) 2.21 (2.20) 1.53 (2.74) 395 (3.2%) 35.44 (5.78)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%) 2.10 (1.55) 1.56 (1.73) 51 (2.6%) 36.38 (6.16)	-0.05 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.04 -0.01 -0.03 -0.01 -0.03 -0.04 -0.01 -0.04 -0.01 -0.04
HbA1c tests; n (%) Imaging/Diagnostics Used in Prostate Cancer 0 1-3 >=4 Internal Medicine/Family Medicine Visits; n (%) Lipid tests; n (%) Microalbuminuria tests; n (%) Number of different/distinct medication prescriptionsmean (sd)median [IQR] Office Visits (outpatient setting only)mean (sd)median [IQR] Oncology Specialist Visit 0 1-5 >=6 Pneumonia vaccine; n (%) Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%) PSA Testmean (sd)median [IQR] Prostate exam for DREmean (sd)median [IQR] Prostate Cancer Oncorbidity Index (PCCI)mean (sd)median [IQR]	1,554 (42.2% 1,717 (46.6% 1,620 (44.0% 344 (9.3%) 3,489 (94.8% 2,689 (73.1%) 921 (25.0%) 8.01 (6.17) 8.00 (3.00, 1: 12.48 (6.80) 11.00 [8.00, : 2,571 (69.8% 455 (12.4%) 655 (17.8%) 958 (26.0%) 18 (0.5%) 2.42 (1.78) 2.00 [1.00, 3. 146 (4.0%) 1.19 (3.27) 0.00 [0.00, 0.	280 (46.9%) 197 (33.0%) 323 (54.1%) 77 (12.9%) 558 (95.1%) 439 (73.5%) 150 (25.1%) 8.27 (6.02) 8.00 [4.00, 1 12.44 (6.38) 11.00 [8.00, 409 (68.5%) 77 (12.9%) 111 (18.6%) 183 (30.7%) 2.40 (1.74) 2.00 [1.00, 3 18 (3.0%) 1.18 (2.90) 0.00 [0.00, 0	-0.09 -0.28 -0.20 -0.11 -0.01 -0.01 -0.02 -0.04 -0.02 -0.02 -0.02 -0.02 -0.10 -0.05 -0.05 -0.00 -0.00 -0.00	570 (19.4%) 1,366 (46.5% 1,243 (42.3% 329 (11.2%) 2,513 (85.5% 1,011 (34.4% 404 (13.8%) 10.22 (5.52) 9.00 [6.00, 1: 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 12.31 (7.03) 11.00 [8.00, : 11.0	97 (22.5%) 132 (30.6%) 217 (50.3%) 82 (19.0%) 377 (87.5%) 152 (35.3%) 10.55 (5.10) 10.00 (7.00, 1 12.46 (6.32) 11.00 [8.00, 1 390 (90.5%) 16 (3.7%) 25 (5.8%) 49 (11.4%) 0 (0.0%) 1.00 (1.51) 0.00 [0.00, 2. 11 (2.6%) 0.31 (1.42) 0.00 [0.00, 0. 34.65 (5.37) 34.00 (30.00,	-0.08 0.33 -0.16 -0.22 -0.06 -0.02 -0.08 -0.09 -0.01 -0.01 -0.01 -0.02 -0.07 -0.06 -0.12 -0.00 -0.12 -0.00 -0.01 -0.01 -0.02 -0.07 -0.02 -0.00	4,510 (77.4% 2,879 (49.4% 2,248 (38.6% 702 (12.0%) 5,219 (89.5% 5,013 (86.0% 2,428 (41.7% 11.92 (5.24) 11.00 (8.00, 1 14.62 (7.67) 13.00 (9.00, 1 3,246 (55.7% 1,059 (18.2% 1,524 (26.1% 1,445 (24.8% 28 (0.5%) 2.59 (1.58) 2.00 [2.00, 3. 132 (2.3%) 0.38 (0.81) 0.00 [0.00, 0.	724 (76.9%) 355 (37.7%) 438 (46.5%) 148 (15.7%) 838 (89.1%) 789 (83.8%) 425 (45.2%) 11.00 [8.00, 1 14.29 (6.95) 13.00 [9.00, 1 1552 (58.7%) 185 (19.7%) 204 (21.7%) 211 2.41 (1.43) 2.00 [1.00, 3. 22 (2.3%) 0.42 (0.82) 0.00 [0.00, 1.	0.01 0.24 -0.16 -0.11 0.01 0.06 -0.07 0.05 0.00 -0.06 -0.04 0.10 -0.11 -0.03 -0.12 -1.33 0.00 -0.05 -0.00 -0.06 -0.04 -0.10 -0.11	6,634 (53.3% 5,962 (47.9% 5,111 (41.1% 1,375 (11.0% 11,221 (90.1' 8,713 (70.0% 3,753 (30.1% 10.36 (5.60) 9.64 (6.20) 13.44 (7.27) 11.94 (8.02) 8,485 (68.2% 1,626 (13.1% 2,337 (18.8% 2,679 (21.5% 53 (0.4%) 2.21 (2.20) 1.53 (2.74) 395 (3.2%) 35.44 (5.78)	1,101 (55.9% 684 (34.7%) 978 (49.7%) 307 (15.6%) 1,783 (90.6% 1,380 (70.1% 647 (32.9%) 10.40 (5.31) 9.87 (5.91) 13.33 (6.65) 11.96 (7.38) 1,351 (68.6% 278 (14.1%) 340 (17.3%) 513 (26.1%) 8 (0.4%) 2.10 (1.55) 1.56 (1.73) 51 (2.6%) 36.38 (6.16) 35.56 (6.74)	-0.05 -0.17 -0.14 -0.02 -0.00 -0.06 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01

Table 1: Unmatched

	F 4 (4 FO()	42 (2.00()	0.04 55 (4.00() 5 (4.00(426 (2.20()	20 (2.40()	0.04 0.45 (0.00()	7 (4 00()	0.04
Anti-arrhythmics; n (%)	54 (1.5%)	12 (2.0%)	-0.04 55 (1.9%) 5 (1.2%			20 (2.1%)		7 (1.9%)	0.01
Anti-diabetic Drugs; n (%)	747 (20.3%)	131 (21.9%)	-0.04 752 (25.6%) 118 (27		3,789 (65.0%	, ,	0.07 5,288 (42.5% 83		0.01
Chemotherapies Used in Prostate Cancer; n (%)	18 (0.5%)	1 (0.2%)	0.05 10 (0.3%) 0 (0.0%		28 (0.5%)	>11		(0.4%)	0.00
Metformin; n (%)	486 (13.2%)	87 (14.6%)	-0.04 388 (13.2%) 68 (15.8		2,144 (36.8%	, ,	0.00 3,018 (24.2% 50		-0.03
Use of anticonvulsants; n (%)	354 (9.6%)	52 (8.7%)	0.03 293 (10.0%) 44 (10.2		901 (15.5%)		0.02 1,548 (12.4% 23		0.02
Use of antidepressants; n (%)	426 (11.6%)	70 (11.7%)	0.00 379 (12.9%) 58 (13.5		1,015 (17.4%		0.06 1,820 (14.6% 27		0.02
Use of Antiparkinsonian Meds; n (%)	51 (1.4%)	13 (2.2%)	-0.06 69 (2.3%) 7 (1.6%		207 (3.6%)	18 (1.9%)	0.10 327 (2.6%) 38	8 (1.9%)	0.05
Use of antiplatelet agents; n (%)	985 (26.8%)	161 (27.0%)	0.00 1,135 (38.6% 162 (37	.6%) 0.02	2,276 (39.0%	356 (37.8%)	0.02 4,396 (35.3% 67	79 (34.5%)	0.02
Use of antipsychotics; n (%)	25 (0.7%)	7 (1.2%)	-0.05 35 (1.2%) 8 (1.9%	-0.06	110 (1.9%)	>11	0.08 170 (1.4%) 24	4 (1.2%)	0.02
Use of anxiolytics/hypnotics; n (%)	137 (3.7%)	25 (4.2%)	-0.03 176 (6.0%) 25 (5.89	%) 0.01	428 (7.3%)	62 (6.6%)	0.03 741 (6.0%) 11	12 (5.7%)	0.01
Use of ARBs; n (%)	573 (15.6%)	100 (16.8%)	-0.03 627 (21.3%) 88 (20.4	1%) 0.02	1,403 (24.1%	230 (24.4%)	-0.01 2,603 (20.9% 41	18 (21.2%)	-0.01
Use of Benzos; n (%)	355 (9.6%)	60 (10.1%)	-0.02 409 (13.9%) 45 (10.4	1%) 0.11	594 (10.2%)	108 (11.5%)	-0.04 1,358 (10.9% 21	13 (10.8%)	0.00
Use of beta blockers; n (%)	1,806 (49.1%	305 (51.1%)	-0.04 1,879 (64.0% 286 (66	.4%) -0.05	3,987 (68.4%	689 (73.2%)	-0.11 7,672 (61.6% 1,	280 (65.0%)	-0.07
Use of bisphosphonate; n (%)	105 (2.9%)	9 (1.5%)	0.10 82 (2.8%) 5 (1.2%	0.11	175 (3.0%)	18 (1.9%)	0.07 362 (2.9%) 32	2 (1.6%)	0.09
Use of calcium channel blockers; n (%)	837 (22.7%)	154 (25.8%)	-0.07 889 (30.3%) 113 (26	.2%) 0.09	1,955 (33.5%	294 (31.2%)	0.05 3,681 (29.6% 56	51 (28.5%)	0.02
Use of COPD/asthma meds; n (%)	468 (12.7%)	82 (13.7%)	-0.03 513 (17.5%) 89 (20.6	5%) -0.08	1,128 (19.4%	166 (17.6%)	0.05 2,109 (16.9% 33	37 (17.1%)	-0.01
Use of Dementia Meds; n (%)	30 (0.8%)	10 (1.7%)	-0.08 63 (2.1%) 8 (1.9%) 0.01	153 (2.6%)	19 (2.0%)	0.04 246 (2.0%) 37	7 (1.9%)	0.01
Use of digoxin; n (%)	53 (1.4%)	12 (2.0%)	-0.05 93 (3.2%) 12 (2.89	%) 0.02	211 (3.6%)	43 (4.6%)	-0.05 357 (2.9%) 67	7 (3.4%)	-0.03
Use of heparin and other low-molecular weight heparins; n (%)	40 (1.1%)	8 (1.3%)	-0.02 62 (2.1%) 7 (1.6%) 0.04	107 (1.8%)	25 (2.7%)	-0.06 209 (1.7%) 40	0 (2.0%)	-0.02
Use of Insulin; n (%)	214 (5.8%)	34 (5.7%)	0.00 223 (7.6%) 34 (7.99	%) -0.01	1,154 (19.8%	186 (19.8%)	0.00 1,591 (12.8% 25	54 (12.9%)	0.00
Use of Lithium; n (%)	6 (0.2%)	0 (0.0%)	0.06 2 (0.1%) 0 (0.0%) 0.04	>11	>11	-0.03 14 (0.1%) 2	(0.1%)	0.00
Use of Loop Diuretics; n (%)	338 (9.2%)	59 (9.9%)	-0.02 395 (13.4%) 61 (14.2	2%) -0.02	1,199 (20.6%	197 (20.9%)	-0.01 1,932 (15.5% 31	17 (16.1%)	-0.02
Use of nitrates; n (%)	524 (14.2%)	75 (12.6%)	0.05 630 (21.4%) 82 (19.0	0.06	1,348 (23.1%	205 (21.8%)	0.03 2,502 (20.1% 36	62 (18.4%)	0.04
Use of NSAIDs; n (%)	405 (11.0%)	74 (12.4%)	-0.04 402 (13.7%) 57 (13.2	2%) 0.01	1,015 (17.4%	132 (14.0%)	0.09 1,822 (14.6% 26	63 (13.4%)	0.03
Use of opioids; n (%)	1,034 (28.1%	173 (29.0%)	-0.02 1,087 (37.0% 171 (39	.7%) -0.06	2,338 (40.1%	369 (39.2%)	0.02 4,459 (35.8% 71	13 (36.2%)	-0.01
Use of oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Warfarin); n (%)	326 (8.9%)	52 (8.7%)	0.01 350 (11.9%) 53 (12.3	3%) -0.01	822 (14.1%)	147 (15.6%)	-0.04 1,498 (12.0% 25	52 (12.8%)	-0.02
Use of oral corticosteroids; n (%)	700 (19.0%)	134 (22.4%)	-0.08 710 (24.2%) 103 (23	.9%) 0.01	1,538 (26.4%	252 (26.8%)	-0.01 2,948 (23.7% 48	89 (24.8%)	-0.03
Use of other antiplatelet agents; n (%)	33 (0.9%)	8 (1.3%)	-0.04 50 (1.7%) 3 (0.7%) 0.09	94 (1.6%)	>11	0.05 177 (1.4%) 20	0 (1.0%)	0.04
Use of other diuretics; n (%)	100 (2.7%)	16 (2.7%)	0.00 122 (4.2%) 22 (5.19	%) -0.04	289 (5.0%)	52 (5.5%)	-0.02 511 (4.1%) 90	0 (4.6%)	-0.02
Use of other hypertension drugs; n (%)	274 (7.4%)	49 (8.2%)	-0.03 266 (9.1%) 32 (7.49	%) 0.06	661 (11.3%)	91 (9.7%)	0.05 1,201 (9.6%) 17	72 (8.7%)	0.03
Use of other lipid-lowering drugs; n (%)	329 (8.9%)	45 (7.5%)	0.05 477 (16.2%) 55 (12.8	3%) 0.10	910 (15.6%)	135 (14.3%)	0.04 1,716 (13.8% 23	35 (11.9%)	0.06
Use of statins; n (%)	2,231 (60.6%		-0.04 2,230 (75.9% 342 (79		4,610 (79.1%	766 (81.4%)	-0.06 9,071 (72.9% 1,		-0.05
Use of thiazide; n (%)	321 (8.7%)	46 (7.7%)	0.04 315 (10.7%) 45 (10.4	1%) 0.01	730 (12.5%)	113 (12.0%)	0.02 1,366 (11.0% 20		0.02
			1 1 1 1 1 1 1				1.4.		

Table 1: Matched

				MATCHED								
		Optum			Marketscan			Medicare			Pooled	
Variable	Leuprolide 54	Degarelix	St. Diff	Leuprolide	Degarelix	St. Diff	Leuprolide	Degarelix	St. Diff	Leuprolide	Degarelix	St. Diff
Number of patients Year of Cohort Entry Date	54	546	5	415	415		926	926		1,887	1,887	4
2008-2009; n (%)		*****			*****		*****					+
2010; n (%)	18 (3.3%)	20 (3.7%)	-0.02	28 (6.7%)	24 (5.8%)	0.04	46 (5.0%)	37 (4.0%)	0.05	92 (4.9%)	81 (4.3%)	0.03
2011; n (%)	26 (4.8%)	23 (4.2%)	0.03		45 (10.8%)		53 (5.7%)	49 (5.3%)		121 (6.4%)	117 (6.2%)	0.01
2012; n (%)	42 (7.7%)	40 (7.3%)	0.02	44 (10.6%)	50 (12.0%)	-0.04	92 (9.9%)	69 (7.5%)	0.09	178 (9.4%)	159 (8.4%)	0.04
2013; n (%)	50 (9.2%)	50 (9.2%)		61 (14.7%)	56 (13.5%)		116 (12.5%)	121 (13.1%)		227 (12.0%)	227 (12.0%)	0.00
2014; n (%)	39 (7.1%)	35 (6.4%)		42 (10.1%)	46 (11.1%)		143 (15.4%)	170 (18.4%)		224 (11.9%)	251 (13.3%)	-0.04
2015; n (%) 2016; n (%)	39 (7.1%)	42 (7.7%)		58 (14.0%)	60 (14.5%) 63 (15.2%)		182 (19.7%)	171 (18.5%) 144 (15.6%)		279 (14.8%) 260 (13.8%)	273 (14.5%) 269 (14.3%)	-0.01
2016; n (%) 2017; n (%)	67 (12.3%) 65 (11.9%)	62 (11.4%) 74 (13.6%)	-0.05	63 (15.2%) 53 (12.8%)	47 (11.3%)	0.00	130 (14.0%) 164 (17.7%)	165 (17.8%)	0.00	282 (14.9%)	286 (15.2%)	-0.01
2018: n (%)	72 (13.2%)	76 (13.9%)		24 (5.8%)	24 (5.8%)	0.00			0.00	202 (24.570)	200 (23.270)	+
2019; n (%)	89 (16.3%)	91 (16.7%)	-0.01			0.00						+
2020; n (%)	39 (7.1%)	33 (6.0%)	0.04									1
Age												
mean (sd)	76.19 (6.92)	76.04 (7.59)		74.65 (9.34)	74.49 (9.17)		76.99 (6.56)	77.02 (6.47)		76.24 (6.74)	76.18 (6.87)	0.01
median [IQR]	77.00 [72.00, 81.00]	76.00 [71.00, 82.00]	0.14	75.00 [67.00, 82.00]	75.00 [68.00, 82.00]	0.00	76.00 [72.00, 82.00]	77.00 [72.00, 82.00]	-0.15	76.07 (7.36)	76.27 (7.46)	-0.03
Region1 - Northeast: n (%)	86 (15.8%)	85 (15.6%)	0.01	04 (22 70/)	92 (22.2%)	0.01	194 (21.0%)	189 (20.4%)	0.01	374 (19.8%)	366 (19.4%)	0.01
1 - Northeast; n (%) 2 - North Central; n (%)	131 (24.0%)	131 (24.0%)		. 94 (22.7%) 0 145 (34.9%)	92 (22.2%) 144 (34.7%)		208 (22.5%)	223 (24.1%)		484 (25.6%)	498 (26.4%)	-0.02
3 - South: n (%)	209 (38.3%)	205 (37.5%)	0.00	139 (33.5%)	130 (31.3%)	0.00	373 (40.3%)	368 (39.7%)		721 (38.2%)	703 (37.3%)	0.02
4 - West: n (%)	120 (22.0%)	125 (22.9%)	-0.02	37 (8.9%)	49 (11.8%)		151 (16.3%)	146 (15.8%)		308 (16.3%)	320 (17.0%)	-0.02
Race					(/	****	(*			†
White; n (%)	437 (80.0%)	438 (80.2%)	-0.01				796 (86.0%)	803 (86.7%)	-0.02	1,233 (65.3%)	1,241 (65.8%)	-0.01
Asian; n (%)	8 (1.5%)	11 (2.0%)	-0.04				<11	<11		13 (0.7%)	19 (1.0%)	-0.03
Black; n (%)	66 (12.1%)	61 (11.2%)	0.03				93 (10.0%)	85 (9.2%)		159 (8.4%)	146 (7.7%)	0.03
Hispanic; n (%)	35 (6.4%)	36 (6.6%)	-0.01			ļ	11 (1.2%)	<11		46 (2.4%)	46 (2.4%)	0.00
North American Native; n (%)			 			 	<11 18 (1.9%)	<11 16 (1.7%)		3 (0.3%) 18 (1.9%)	4 (0.4%) 16 (1.7%)	-0.02
Other; n (%) Cardiovascular event prognosticators			1			l	10 (1.970)	10 (1.770)	0.02	10 (1.3%)	10 (1./70)	0.02
Acute or Old MI; n (%)	204 (37.4%)	212 (38.8%)	-0.03	97 (23.4%)	94 (22.7%)	0.02	357 (38.6%)	348 (37.6%)	0.02	658 (34.9%)	654 (34.7%)	0.00
Anxiety; n (%)	32 (5.9%)	33 (6.0%)		20 (4.8%)	22 (5.3%)		60 (6.5%)	57 (6.2%)		112 (5.9%)	112 (5.9%)	0.00
Atrial Fibrillation; n (%)	84 (15.4%)	90 (16.5%)		62 (14.9%)	70 (16.9%)		187 (20.2%)	206 (22.2%)		333 (17.6%)	366 (19.4%)	-0.05
Coronary Atherosclerosis; n (%)	436 (79.9%)	432 (79.1%)	0.02		302 (72.8%)		764 (82.5%)	762 (82.3%)		1,505 (79.8%)	1,496 (79.3%)	0.01
Coronary, Carotid, Illiac, Femoral, and Popliteal Revascularization (Angioplasty/Stent/CABG); n (%)	30 (5.5%)	43 (7.9%)		40 (9.6%)	32 (7.7%)	0.07	63 (6.8%)	70 (7.6%)		133 (7.0%)	145 (7.7%)	-0.03
Diabetes with Complications; n (%)	181 (33.2%)	186 (34.1%)	-0.02		58 (14.0%)		745 (80.5%)	724 (78.2%)		988 (52.4%)	968 (51.3%)	0.02
Diabetes without Complications; n (%)	98 (17.9%)	116 (21.2%)		149 (35.9%)	134 (32.3%)		340 (36.7%)	351 (37.9%)		587 (31.1%)	601 (31.8%)	-0.02
DVT; n (%) Edema: n (%)	24 (4.4%) 60 (11.0%)	23 (4.2%) 60 (11.0%)		7 (1.7%)	6 (1.4%) 28 (6.7%)		45 (4.9%) 136 (14.7%)	42 (4.5%) 135 (14.6%)		76 (4.0%) 226 (12.0%)	71 (3.8%) 223 (11.8%)	0.01
Erectile dysfunction; n (%)	79 (14.5%)	77 (14.1%)		39 (9.4%)	42 (10.1%)		121 (13.1%)	121 (13.1%)		239 (12.7%)	240 (12.7%)	0.00
Foot ulcer: n (%)	12 (2.2%)	18 (3.3%)		9 (2.2%)	10 (2.4%)		48 (5.2%)	48 (5.2%)		69 (3.7%)	76 (4.0%)	-0.02
Hyperlipidemia; n (%)	459 (84.1%)	467 (85.5%)	-0.04	300 (72.3%)	290 (69.9%)	0.05	837 (90.4%)	843 (91.0%)	-0.02	1,596 (84.6%)	1,600 (84.8%)	-0.01
Hypertension; n (%)	477 (87.4%)	479 (87.7%)		313 (75.4%)	318 (76.6%)	-0.03	862 (93.1%)	867 (93.6%)	-0.02	1,652 (87.5%)	1,664 (88.2%)	-0.02
Intracranial or Retroperitoneal Hemorrhage; n (%)	7 (1.3%)	5 (0.9%)	0.04	4 (1.0%)	3 (0.7%)		12 (1.3%)	17 (1.8%)		23 (1.2%)	25 (1.3%)	-0.01
Ischemic Heart Disease; n (%)	461 (84.4%)	457 (83.7%)		325 (78.3%)	319 (76.9%)		795 (85.9%)	791 (85.4%)		1,581 (83.8%)	1,567 (83.0%)	0.02
Ischemic Stroke; n (%)	101 (18.5%)	101 (18.5%)		77 (18.6%)	76 (18.3%)		228 (24.6%)	229 (24.7%)		406 (21.5%)	406 (21.5%)	0.00
Major Trauma; n (%)	21 (3.8%)	27 (4.9%) 59 (10.8%)		22 (5.3%) 55 (13.3%)	18 (4.3%) 45 (10.8%)		65 (7.0%) 147 (15.9%)	55 (5.9%) 159 (17.2%)		108 (5.7%) 268 (14.2%)	100 (5.3%) 263 (13.9%)	0.02
Obesity; n (%) Other Disorders of Thyroid Gland; n (%)	66 (12.1%) 12 (2.2%)	16 (2.9%)		16 (3.9%)	13 (3.1%)		34 (3.7%)	38 (4.1%)		62 (3.3%)	67 (3.6%)	-0.02
Overweight; n (%)	38 (7.0%)	40 (7.3%)		10 (2.4%)	13 (3.1%)		41 (4.4%)	42 (4.5%)		89 (4.7%)	95 (5.0%)	-0.02
PE; n (%)	10 (1.8%)	8 (1.5%)	0.02	2 (0.5%)	2 (0.5%)		<11	14 (1.5%)	-0.04	22 (1.2%)	24 (1.3%)	-0.01
Peripheral Vascular Disease; n (%)	191 (35.0%)	185 (33.9%)	0.02	109 (26.3%)	111 (26.7%)		284 (30.7%)	272 (29.4%)	0.03	584 (30.9%)	568 (30.1%)	0.02
Stable Angina; n (%)	62 (11.4%)	75 (13.7%)		38 (9.2%)	34 (8.2%)		107 (11.6%)	112 (12.1%)		207 (11.0%)	221 (11.7%)	-0.02
Systemic Embolism; n (%)	9 (1.6%)	8 (1.5%)		9 (2.2%)	9 (2.2%)		<11	<11	-0.05	24 (1.3%)	27 (1.4%)	-0.01
TIA; n (%)	19 (3.5%)	19 (3.5%)	0.00	8 (1.9%)	10 (2.4%)	-0.03	35 (3.8%)	36 (3.9%)	-0.01	62 (3.3%)	65 (3.4%)	-0.01
General Health/Mortality Prognosticators Abnormal liver function: n (%)	57 (10.4%)	53 (9.7%)	0.03	31 (7.5%)	27 (6.5%)	0.04	103 (11.1%)	97 (10.5%)	0.03	191 (10.1%)	177 (9.4%)	0.02
Alcohol Abuse/Dependence: n (%)	19 (3.5%)	15 (2.7%)		5 (1.2%)	5 (1.2%)		18 (1.9%)	19 (2.1%)		42 (2.2%)	39 (2.1%)	0.02
Anemias (Sickle-Cell, GGPD Deficiency, Nutrient Deficiency): n (%)	129 (23.6%)	141 (25.8%)		81 (19.5%)	68 (16.4%)		282 (30.5%)	280 (30.2%)		492 (26.1%)	489 (25.9%)	0.00
Asthma; n (%)	23 (4.2%)	21 (3.8%)		21 (5.1%)	21 (5.1%)		60 (6.5%)	58 (6.3%)		104 (5.5%)	100 (5.3%)	0.01
COPD; n (%)	127 (23.3%)	125 (22.9%)	0.01	. 84 (20.2%)	74 (17.8%)	0.06	236 (25.5%)	221 (23.9%)	0.04	447 (23.7%)	420 (22.3%)	0.0
Delirium; n (%)	15 (2.7%)	14 (2.6%)		4 (1.0%)	4 (1.0%)	0.00	34 (3.7%)	34 (3.7%)		53 (2.8%)	52 (2.8%)	0.00
Dementia; n (%)	17 (3.1%)	18 (3.3%)		11 (2.7%)	9 (2.2%)		24 (2.6%)	30 (3.2%)		52 (2.8%)	57 (3.0%)	-0.01
Depression; n (%)	49 (9.0%)	45 (8.2%)		23 (5.5%)	22 (5.3%) 10 (2.4%)		72 (7.8%)	76 (8.2%)		144 (7.6%)	143 (7.6%)	-0.04
Falls; n (%) Fractures: n (%)	31 (5.7%) 35 (6.4%)	38 (7.0%) 29 (5.3%)		10 (2.4%)	10 (2.4%) 21 (5.1%)		60 (6.5%) 44 (4.8%)	71 (7.7%) 45 (4.9%)		101 (5.4%) 101 (5.4%)	119 (6.3%) 95 (5.0%)	-0.04
Fractures; n (%) HIV/AIDS: n (%)	0 (0.0%)	29 (5.3%)		0 (0.0%)	0 (0.0%)	0.01 N/A	0 (0.0%)	45 (4.9%) <11		0 (0.0%)	95 (5.0%) 05 (0.3%)	-0.02
Organ Transplant; n (%)	1 (0.2%)	3 (0.5%)		4 (1.0%)	4 (1.0%)	1975	<11	<11		8 (0.4%)	11 (0.6%)	-0.03
Osteoporosis; n (%)	29 (5.3%)	23 (4.2%)	0.05	14 (3.4%)	12 (2.9%)	0.03	48 (5.2%)	54 (5.8%)	-0.03	91 (4.8%)	89 (4.7%)	0.00
Peptic Ulcer Disease; n (%)	142 (26.0%)	141 (25.8%)	0.00	73 (17.6%)	72 (17.3%)		249 (26.9%)	254 (27.4%)	-0.01	464 (24.6%)	467 (24.7%)	0.00
Pneumonia; n (%)	19 (3.5%)	15 (2.7%)		11 (2.7%)	15 (3.6%)	-0.05	18 (1.9%)	19 (2.1%)	-0.01	48 (2.5%)	49 (2.6%)	-0.01
Renal Failure; n (%)	123 (22.5%)	127 (23.3%)		56 (13.5%)	56 (13.5%)	0.00	246 (26.6%)	246 (26.6%)	0.00	425 (22.5%)	429 (22.7%)	0.00
Renal Failure (CKD Stage 4 or higher); n (%)	17 (3.1%)	17 (3.1%)		10 (2.4%)	12 (2.9%)		47 (5.1%)	49 (5.3%)		74 (3.9%)	78 (4.1%)	-0.01
Sleep Apnea; n (%) Sleep Disorder: n (%)	46 (8.4%) 27 (4.9%)	52 (9.5%) 29 (5.3%)		42 (10.1%)	43 (10.4%) 38 (9.2%)		96 (10.4%) 82 (8.9%)	106 (11.4%) 101 (10.9%)		184 (9.8%) 135 (7.2%)	201 (10.7%) 168 (8.9%)	-0.03 -0.06
Sieep Disorder; n (%) Smoking: n (%)	27 (4.9%)	29 (5.3%) 178 (32.6%)		26 (6.3%)	38 (9.2%) 66 (15.9%)		82 (8.9%) 270 (29.2%)	290 (31.3%)		135 (7.2%) 527 (27.9%)	168 (8.9%)	-0.06
Frailty Score: Empirical Version 365 days (ICD-9 and ICD-10) v2	204 (33.770)	2,0(32.0/0)	0.02		(13.3/0)	0.05	210(23.270)	230 (31.370)	-0.05	JE1 (41.370)	JJ+ (20.J/II)	-0.0
mean (sd)	0.16 (0.05)	0.16 (0.05)	0.00	0.16 (0.05)	0.16 (0.05)	0.00	0.19 (0.06)	0.19 (0.06)	0.00	0.17 (0.05)	0.17 (0.05)	0.00
median [IQR]	0.15 [0.13, 0.19]	0.16 [0.13, 0.19]		0.15 [0.13, 0.18]	0.15 [0.13, 0.19]		0.18 [0.15, 0.22]	0.18 [0.15, 0.22]		0.16 (0.06)	0.17 (0.06)	-0.17
Healthcare utilization												
Any hospitalization; n (%)	109 (20.0%)	133 (24.4%)		89 (21.4%)	90 (21.7%)		242 (26.1%)	244 (26.3%)		440 (23.3%)	467 (24.7%)	-0.03
Bone mineral density; n (%)	23 (4.2%)	20 (3.7%)		11 (2.7%)	9 (2.2%)		41 (4.4%)	41 (4.4%)		75 (4.0%)	70 (3.7%)	0.02
BUN tests; n (%)	82 (15.0%)	82 (15.0%)	0.00	55 (13.3%)	45 (10.8%)	0.08	181 (19.5%)	183 (19.8%)	-0.01	318 (16.9%)	310 (16.4%)	0.01
Cardiologist visit	203 (37.2%)	189 (34.6%)		181 (43.6%)	187 (45.1%)		200 (21.6%)	194 (21.0%)		584 (30.9%)	570 (30.2%)	0.03
1-2	203 (37.2%)	189 (34.6%) 164 (30.0%)	-0.05		187 (45.1%)		200 (21.6%) 336 (36.3%)	194 (21.0%) 320 (34.6%)		584 (30.9%) 610 (32.3%)	570 (30.2%) 592 (31.4%)	0.02
1-2 3-5	132 (24.2%)	164 (30.0%)		75 (18.1%)	75 (18.1%)		241 (26.0%)	249 (26.9%)		610 (32.3%) 448 (23.7%)	592 (31.4%) 455 (24.1%)	-0.01
206 206	132 (24.2%) 51 (9.3%)	131 (24.0%) 62 (11.4%)	-0.00		75 (18.1%) 45 (10.8%)		149 (16.1%)	163 (17.6%)	-0.02	245 (13.0%)	455 (24.1%) 270 (14.3%)	-0.04
	67 (12.3%)	65 (11.9%)		44 (10.6%)	41 (9.9%)		91 (9.8%)	108 (11.7%)		202 (10.7%)	214 (11.3%)	-0.02
Colonoscopy: n (%)												
Colonoscopy; n (%) Endocrinologist Visit; n (%)	17 (3.1%)	19 (3.5%)	-0.02	13 (3.1%)	15 (3.6%)	-0.03	70 (7.6%)	90 (9.7%)	-0.07	100 (5.3%)	124 (6.6%)	-0.05

Table 1: Matched

Flu vaccine; n (%) Glucose tests; n (%) Glucose tests; n (%)	222 (40.7%)				0.03 599 (64.7%)			905 (48.0%)	888 (47.1%)	0.0
	6 (1.1%)	204 (37.4%) 12 (2.2%)	0.07 84 (20.2%) -0.09 8 (1.9%)	79 (19.0%) 8 (1.9%)	0.00 59 (6.4%)	605 (65.3%) 63 (6.8%)		73 (3.9%)	83 (4.4%)	-0.0
	74 (13.6%)	91 (16.7%)	-0.09 73 (17.6%)	54 (13.0%)	0.13 268 (28.9%)	271 (29.3%)		415 (22.0%)	416 (22.0%)	0.0
HbA1c tests : n (%)	246 (45.1%)	249 (45.6%)	-0.01 101 (24.3%)	92 (22.2%)	0.05 712 (76.9%)	712 (76.9%)		1,059 (56.1%)	1.053 (55.8%)	0.0
Imaging/Diagnostics Used in Prostate Cancer	240 (43.170)	243 (43.0%)	-0.01 101 (24.3%)	32 (22.270)	0.03 712 (70.5%)	712 (70.570)	0.00	1,033 (30.170)	1,033 (33.676)	0.0
niagnig/ biagnostics osed in Frostate cancer	177 (32.4%)	181 (33.2%)	-0.02 128 (30.8%)	132 (31.8%)	-0.02 332 (35.9%)	348 (37.6%)	.0.0.	637 (33.8%)	661 (35.0%)	-0.0
1.3	304 (55.7%)	296 (54.2%)	0.03 209 (50.4%)	208 (50.1%)	0.01 449 (48.5%)	433 (46.8%)		962 (51.0%)	937 (49.7%)	0.0
5-A	65 (11.9%)	69 (12.6%)	-0.02 78 (18.8%)	75 (18.1%)	0.02 145 (15.7%)	145 (15.7%)		288 (15.3%)	289 (15.3%)	0.0
Internal Medicine/Family Medicine Visits; n (%)	512 (93.8%)	521 (95.4%)	-0.07 368 (88.7%)	364 (87.7%)	0.03 827 (89.3%)	824 (89.0%)		1,707 (90.5%)	1,709 (90.6%)	0.0
Lipid tests; n (%)	407 (74.5%)	402 (73.6%)	0.02 151 (36.4%)	146 (35.2%)	0.03 770 (83.2%)	775 (83.7%)		1,328 (70.4%)	1,323 (70.1%)	0.0
Microalbuminuria tests; n (%)	129 (23.6%)	138 (25.3%)	-0.04 70 (16.9%)	66 (15.9%)	0.03 423 (45.7%)	419 (45.2%)		622 (33.0%)	623 (33.0%)	0.0
Number of different/distinct medication prescriptions	123 (23.0%)	138 (23.3%)	-0.04 70 (10.5%)	00 (13.370)	0.03 423 (43.7%)	415 (45.270)	0.0.	022 (33.070)	023 (33.0%)	0.0
mean (sd)	8.05 (5.80)	8.22 (6.03)	-0.03 10.77 (5.60)	10.45 (5.00)	0.06 11.62 (4.86)	11.67 (4.91)	.0.0	10.40 (4.84)	10.40 (4.79)	0.0
median [IQR]	8.00 [4.00, 12.00]	8.00 [4.00, 12.00]	0.00 10.00 [7.00, 14.00]	10.00 [7.00, 13.00]	0.00 11.02 (4.80)	11.00 [8.00, 15.00]		9.91 (5.31)	9.91 (5.28)	0.0
Office Visits (outpatient setting only)	8.00 [4.00, 12.00]	8.00 [4.00, 12.00]	0.00 [0.00 [7.00, 14.00]	10.00 [7.00, 13.00]	0.00 [1.00 [8.00, 13.00]	11.00 [0.00, 13.00]	0.00	3.31 (3.31)	9.91 (3.26)	0.0
	12.19 (6.15)	12.35 (6.28)	-0.03 13.06 (6.91)	12.48 (6.36)	0.09 13.78 (6.87)	14.30 (6.98)	.0.0	13.16 (5.92)	13.34 (5.86)	-0.0
mean (sd)median [IQR]	11.00 [8.00, 15.00]	11.00 [8.00, 15.00]		11.00 [8.00, 16.00]	0.15 13.00 [9.00, 17.00]	13.00 [9.00, 18.00]		12.20 (6.68)	11.98 (6.65)	0.0
Oncology Specialist Visit	11.00 [8.00, 13.00]	11.00 [8.00, 13.00]	0.00 12.00 [8.00, 16.00]	11.00 [8.00, 16.00]	0.13 13.00 [9.00, 17.00]	13.00 [9.00, 18.00]	0.00	12.20 (0.00)	11.98 (6.63)	0.0
on cology specialist visit	370 (67.8%)	370 (67.8%)	0.00 368 (88.7%)	375 (90.4%)	-0.06 565 (61.0%)	546 (59.0%)	0.0	1.303 (69.1%)	1.291 (68.4%)	0.0
J										-0.0
1-0	73 (13.4%) 103 (18.9%)	72 (13.2%) 104 (19.0%)	0.01 18 (4.3%)	16 (3.9%) 24 (5.8%)	0.02 166 (17.9%) 0.05 195 (21.1%)	181 (19.5%) 199 (21.5%)		257 (13.6%) 327 (17.3%)	269 (14.3%) 327 (17.3%)	-0.0
Page mania yangina n (9/)	174 (31.9%)	104 (19.0%)	0.00 29 (7.0%)	24 (5.8%) 48 (11.6%)	-0.03 257 (21.1%)	199 (21.5%) 275 (29.7%)		476 (25.2%)	327 (17.3%) 497 (26.3%)	-0.0
Pneumonia vaccine; n (%)	1/4 (31.9%)	1/4 (31.9%)	0.00 45 (10.8%)	40 (11.0%)	-0.03 257 (27.8%)	210 (29.1%)	-0.04	470 (25.2%)	497 (26.3%)	-0.0
Prostate cancer prognosticators Radiation Therapies Used in Prostate Cancer; n (%)	3 (0.5%)	1 (0.2%)	0.05 1 (0.2%)	0 (0.0%)	0.06 <11	<11	0.00	8 (0.4%)	8 (0.4%)	0.0
	3 (0.5%)	1 (0.2%)	0.05 1 (0.2%)	0 (0.0%)	0.06 <11	<11	-0.0:	8 (0.4%)	8 (0.4%)	0.0
PSA Test	2 20 (4 00)	2 44 (4 75)	0.03 0.04 (4.45)	4.04 (4.52)	0.05(3.33/4.40)	2.40 (1.42)		2.04 (4.40)	2 40 (4 44)	+
mean (sd)	2.38 (1.80)	2.41 (1.75)	-0.02 0.94 (1.45)	1.01 (1.53)	-0.05 2.33 (1.40)			2.04 (1.40)	2.10 (1.41)	0.0
median [IQR]	2.00 [1.00, 3.00]	2.00 [1.00, 3.25]	0.00 0.00 [0.00, 2.00]	0.00 [0.00, 2.00]	0.00 2.00 [1.00, 3.00]	2.00 [1.00, 3.00]		1.56 (1.54)	1.56 (1.55)	0.0
Prostatectomy; n (%)	14 (2.6%)	17 (3.1%)	-0.03 16 (3.9%)	11 (2.7%)	-0.24 22 (2.4%)	21 (2.3%)	-0.2.	52 (2.8%)	49 (2.6%)	0.0
Prostate exam for DRE				/>		/				
mean (sd)	1.27 (3.29)	1.17 (2.84)	0.03 0.33 (1.34)	0.30 (1.42)	0.02 0.45 (0.90)	0.42 (0.82)		0.66 (1.94)	0.61 (1.72)	0.0
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00 0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00 0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 (1.98)	0.00 (1.76)	0.0
Prostate Cancer Comorbidity Index (PCCI)					ļ					
mean (sd)	36.39 (6.41)	36.50 (6.31)	-0.02 34.75 (5.72)	34.42 (5.19)	0.06 37.00 (6.38)	36.99 (6.21)		36.33 (5.55)	36.28 (5.35)	0.0
median [IQR]	35.00 [32.00, 40.00]	35.00 [32.00, 40.00]	0.00 34.00 [30.00, 38.00]	34.00 [30.00, 37.00]	0.00 36.00 [32.00, 41.00]	36.00 [33.00, 41.00]	0.00	35.27 (6.25)	35.27 (6.03)	0.0
Medications										
ACE inhibitors; n (%)	179 (32.8%)	178 (32.6%)	0.00 162 (39.0%)	173 (41.7%)	-0.06 446 (48.2%)	453 (48.9%)		787 (41.7%)	804 (42.6%)	-0.0
Anti-arrhythmics; n (%)	9 (1.6%)	11 (2.0%)	-0.03 7 (1.7%)	5 (1.2%)	0.04 11 (1.2%)	19 (2.1%)		27 (1.4%)	35 (1.9%)	-0.0
Anti-diabetic Drugs; n (%)	116 (21.2%)	114 (20.9%)	0.01 114 (27.5%)	111 (26.7%)	0.02 582 (62.9%)	574 (62.0%)		812 (43.0%)	799 (42.3%)	0.0
Chemotherapies Used in Prostate Cancer; n (%)	3 (0.5%)	1 (0.2%)	0.05 1 (0.2%)	0 (0.0%)	0.06 <11	<11		8 (0.4%)	8 (0.4%)	0.0
Metformin; n (%)	73 (13.4%)	77 (14.1%)	-0.02 76 (18.3%)	62 (14.9%)	0.09 320 (34.6%)	341 (36.8%)		469 (24.9%)	480 (25.4%)	-0.0
Use of anticonvulsants; n (%)	46 (8.4%)	49 (9.0%)	-0.02 44 (10.6%)	41 (9.9%)	0.02 128 (13.8%)	135 (14.6%)		218 (11.6%)	225 (11.9%)	-0.0
Use of antidepressants; n (%)	67 (12.3%)	64 (11.7%)	0.02 46 (11.1%)	53 (12.8%)	-0.05 144 (15.6%)	142 (15.3%)		257 (13.6%)	259 (13.7%)	0.0
Use of Antiparkinsonian Meds; n (%)	10 (1.8%)	10 (1.8%)	0.00 6 (1.4%)	7 (1.7%)	-0.02 20 (2.2%)	18 (1.9%)		36 (1.9%)	35 (1.9%)	0.0
Use of antiplatelet agents; n (%)	143 (26.2%)	142 (26.0%)	0.00 164 (39.5%)	153 (36.9%)	0.05 358 (38.7%)	348 (37.6%)		665 (35.2%)	643 (34.1%)	0.0
Use of antipsychotics; n (%)	6 (1.1%)	6 (1.1%)	0.00 4 (1.0%)	7 (1.7%)	-0.06 <11	<11		20 (1.1%)	22 (1.2%)	-0.0
Use of anxiolytics/hypnotics; n (%)	24 (4.4%)	23 (4.2%)	0.01 22 (5.3%)	24 (5.8%)	-0.02 57 (6.2%)	62 (6.7%)		103 (5.5%)	109 (5.8%)	-0.0
Use of ARBs; n (%)	81 (14.8%)	87 (15.9%)	-0.03 90 (21.7%)	86 (20.7%)	0.02 248 (26.8%)	228 (24.6%)		419 (22.2%)	401 (21.3%)	0.0
Use of Benzos; n (%)	51 (9.3%)	54 (9.9%)		44 (10.6%)	0.03 98 (10.6%)	103 (11.1%)		197 (10.4%)	201 (10.7%)	-0.0
Use of beta blockers; n (%)	273 (50.0%)	278 (50.9%)	-0.02 268 (64.6%)	276 (66.5%)	-0.04 668 (72.1%)	675 (72.9%)		1,209 (64.1%)	1,229 (65.1%)	-0.0
Use of bisphosphonate; n (%)	12 (2.2%)	9 (1.6%)	0.04 11 (2.7%)	5 (1.2%)	0.11 18 (1.9%)	18 (1.9%)		41 (2.2%)	32 (1.7%)	0.0
Use of calcium channel blockers; n (%)	144 (26.4%)	144 (26.4%)	0.00 110 (26.5%)	108 (26.0%)	0.01 288 (31.1%)	291 (31.4%)		542 (28.7%)	543 (28.8%)	0.0
Use of COPD/asthma meds; n (%)	75 (13.7%)	78 (14.3%)	-0.02 93 (22.4%)	82 (19.8%)	0.06 172 (18.6%)	163 (17.6%)		340 (18.0%)	323 (17.1%)	0.0
Use of Dementia Meds; n (%)	6 (1.1%)	8 (1.5%)	-0.04 11 (2.7%)	8 (1.9%)	0.05 20 (2.2%)	19 (2.1%)		37 (2.0%)	35 (1.9%)	0.0
Use of digoxin; n (%)	9 (1.6%)	10 (1.8%)	-0.02 11 (2.7%)	12 (2.9%)	-0.01 31 (3.3%)	43 (4.6%)		51 (2.7%)	65 (3.4%)	-0.0
Use of heparin and other low-molecular weight heparins; n (%)	4 (0.7%)	6 (1.1%)	-0.04 9 (2.2%)	6 (1.4%)	0.06 26 (2.8%)	25 (2.7%)		39 (2.1%)	37 (2.0%)	0.0
Use of Insulin; n (%)	23 (4.2%)	28 (5.1%)	-0.04 30 (7.2%)	32 (7.7%)	-0.02 174 (18.8%)	184 (19.9%)		227 (12.0%)	244 (12.9%)	-0.0
Use of Lithium; n (%)	1 (0.2%)	0 (0.0%)	0.06 0 (0.0%)	0 (0.0%)	N/A <11	<11		2 (0.1%)	2 (0.1%)	0.0
Use of Loop Diuretics; n (%)	45 (8.2%)	52 (9.5%)	-0.05 51 (12.3%)	58 (14.0%)	-0.05 186 (20.1%)	195 (21.1%)		282 (14.9%)	305 (16.2%)	-0.0
Use of nitrates; n (%)	74 (13.6%)	69 (12.6%)	0.03 74 (17.8%)	77 (18.6%)	-0.02 198 (21.4%)	201 (21.7%)		346 (18.3%)	347 (18.4%)	0.0
Use of NSAIDs; n (%)	71 (13.0%)	69 (12.6%)	0.01 62 (14.9%)	57 (13.7%)	0.03 141 (15.2%)	128 (13.8%)		274 (14.5%)	254 (13.5%)	0.0
Use of opioids; n (%)	169 (31.0%)	159 (29.1%)	0.04 158 (38.1%)	162 (39.0%)	-0.02 376 (40.6%)	361 (39.0%)		703 (37.3%)	682 (36.1%)	0.0
Use of oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Warfarin); n (%)	46 (8.4%)	46 (8.4%)	0.00 51 (12.3%)	51 (12.3%)	0.00 138 (14.9%)	147 (15.9%)	-0.0	235 (12.5%)	244 (12.9%)	-0.0
Use of oral corticosteroids; n (%)	126 (23.1%)	124 (22.7%)	0.01 110 (26.5%)	100 (24.1%)	0.06 277 (29.9%)	246 (26.6%)		513 (27.2%)	470 (24.9%)	0.0
Use of other antiplatelet agents; n (%)	8 (1.5%)	5 (0.9%)	0.06 4 (1.0%)	3 (0.7%)	0.03 <11	<11	-0.0	17 (0.9%)	17 (0.9%)	0.0
	16 (2.9%)	16 (2.9%)	0.00 29 (7.0%)	21 (5.1%)	0.08 48 (5.2%)	51 (5.5%)	-0.0	93 (4.9%)	88 (4.7%)	0.0
Use of other diuretics; n (%)		47 (0.00/)		31 (7.5%)	-0.03 96 (10.4%)	90 (9.7%)	0.0	168 (8.9%)	168 (8.9%)	0.0
Use of other diuretics; n (%) Use of other hypertension drugs; n (%)	44 (8.1%)	47 (8.6%)	-0.02 28 (6.7%)	31 (7.3%)						
	44 (8.1%) 37 (6.8%)	41 (7.5%)	-0.02 28 (6.7%)	51 (12.3%)	-0.05 131 (14.1%)	132 (14.3%)		213 (11.3%)	224 (11.9%)	-0.0
Use of other hypertension drugs; n (%)							-0.0			